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Abstract 
Creating accurate, high quality measurement with patient-reported outcomes (PRO) is a 
key challenge for developers. It is often the case that PRO measures fail to clearly define 
the constructs that they are intended to measure. Consequently, they fail to provide 
measurement that is valid and meaningful.  
Classical test theory has been applied in the development of most outcome measures 
currently in use. Such psychometric approaches to PRO measure development are being 
superseded by more powerful item response theory (IRT) methods. The Rasch model is the 
one parameter form of IRT that embodies fundamental measurement requirements. Scales 
that produce data fitting the Rasch model provide interval level measurement, improving 
their power and discrimination. 
The thesis argues that it is a combination of clear construct definition and application of 
Rasch analysis that lead to improved measurement. 
The aims of the thesis are to i) describe approaches to construct definition and 
psychometric measurement ii) evaluate my own research in relation to these approaches 
iii) critically assess the contribution of the research to the field.        
The thesis considers ten articles relating to the development and application of PROs. The 
articles in the thesis cover the following topics: 
New PRO scale developments. Three articles describe developments of new measures that 
are based on a clearly defined construct and apply Rasch analysis in their development.   
Application of PRO scales in international research. Two articles describe the adaptation of 
PRO scales into several additional languages. Such adaptations increase the value of the 
measures to international research. In addition, a minimal important difference (MID) 
study is described in one article. The MID estimations generated assist the interpretation of 
scores and sample size determination for future studies.    
Evaluation of existing PRO scales. Three studies describing the evaluation of PRO measures 
are discussed. Weaknesses were identified in each of the scales. The Mood Disorder 
Questionnaire, a screening tool for bipolar disorder, was found to screen patients more 
effectively when the symptoms section of the scale was used without the other sections of 
the questionnaire. The Dermatology Life Quality Index (DLQI) and the SF-36 had several 
measurement limitations and were not based on clearly defined constructs.  
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Co-calibration of disease-specific PRO scales. A new method for combining scores from two 
disease-specific PROs using Rasch analysis is discussed. This method offers a means of 
combining PRO data from patients with different diseases that complete different disease-
specific measures. This approach was possible as both measures were developed based on 
the same clearly defined construct and both produced data fitting the Rasch model.  
The research makes a number of important contributions to the improvement of PRO 
measurement. The studies show that clear construct definition and application of Rasch 
analysis are central to improving the science. More work is necessary, particularly to 
understand in greater detail the needs-based model of quality of life that has been applied 
in the new measure development described in the thesis.   
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Chapter 1: Introduction 
1.1 Background 
For the last ten years I have been part of a research group specialising in the development 
of patient reported outcome (PRO) measures.  In essence, these types of outcomes take 
the form of questionnaires and provide a means for patients to report on the impact of a 
disease from their own perspective. During this time I became aware not only of the 
importance of capturing the patients experience but also of measuring it accurately. My 
research interests have focussed on trying to improve the science of measurement in this 
area.   
As scientists, we attempt to acquire and organise knowledge about phenomena into 
testable predictions and observations. Central to this process is the ability to create 
accurate and meaningful measurements. These then become the foundation of 
information about the phenomenon of interest and can be used to make predictions. In the 
physical sciences great emphasis has been made on producing accurate measurements of 
concepts such as temperature, mass and length (Taylor, 1991). It is vital that the same kind 
of rigorous approach is applied to measuring the impact of health conditions. The 
importance of accurate measurement is described eloquently by one of the pioneers of 
scientific measurement (Kelvin, 1883): 
"I often say that when you can measure what you are speaking about, and express it in 
numbers, you know something about it; but when you cannot measure it, when you cannot 
express it in numbers, your knowledge is of a meagre and unsatisfactory kind; it may be the 
beginning of knowledge, but you have scarcely in your thoughts advanced to the state of 
Science, whatever the matter may be."  
Health outcomes can be measured in a variety of ways. In clinical trials, physiological 
measures are the most frequent form of primary outcome (Doward et al, 2010). These 
measures focus on assessing the physical manifestations of a disease. For example, in 
cardiology disease various measurements of cardiac output and blood flow can be taken to 
reflect the functioning of the heart. Although physiological measures can provide detailed 
information regarding the disease they may be invasive, expensive, time consuming and 
difficult to use on a regular basis. Crucially, these outcomes provide only limited 
perspective on a disease and as such may not accurately reflect the impact the disease or 
intervention has on the patient. 
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PRO data provide an alternative method of gaining information on the impact of a disease 
and offer several advantages. First, PROs allow the patient to provide their perspective on 
how their illness affects them. Patients’ views often correlate poorly with physical 
assessments (Piquette et al, 2000; Jones, 2001) and differ to those of clinicians (Hewlett, 
2003; Martin et al, 2009; Wehmeier et al, 2007). Patients are more likely to focus on the 
psychological and broader impact of an illness rather than on its physical effects (Neville et 
al, 2000; Doward et al, 2009a). Importantly, the broader aspects of an illness, such as 
participation and quality of life, can only be assessed accurately by the patient.  
Various stakeholders have an interest in seeing the patient-perceived benefits of 
interventions including patient groups, payers, regulators, policy makers, health technology 
assessment bodies and clinicians (Doward et al, 2010). The ease with which PRO data can 
be incorporated into research studies compared with invasive physiological assessments 
also makes their use attractive. These factors have led to the increased use of PROs in 
clinical trials (Scoggins and Patrick, 2009). Despite the potential benefits, creating accurate 
measurements using PROs has been extremely challenging for developers and methods 
have lagged behind measurement in the physical sciences.     
Until recently, classical test theory (CTT) psychometric approaches dominated the field of 
PRO development. These approaches are based on true score theory (Allen and Yen, 2002; 
Novick, 1996; Traub, 1997). They focus on total score level data and error associated with 
it. Using this approach the distances between each item in terms of the amount of 
construct measured is not known. The end result is an ordinal based measure with limited 
mathematical qualities. For example, only less powerful non-parametric statistical 
techniques are justified with this level of data and calculation of change scores in clinical 
trials is not justified (Tennant et al, 2004).  
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A major shift in the approach to measurement has occurred in recent years due to the 
application of Item Response Theory (IRT). IRT is a paradigm for the scoring, interpretation 
and analysis of tests (Hambleton et al, 1991). It is based on the premise that the selection 
of a response to an item is a probabilistic mathematical function of the amount of difficulty 
represented by the item and the level of trait that the person exhibits (Hambleton et al, 
1991). By modelling responses to items they can be located on an underlying metric in 
order of severity. This contrasts with classical psychometric approaches that do not make 
any assumption regarding the amount of construct represented by the items. The ‘item’ 
level diagnostic information provided by IRT methods makes the approach a much more 
powerful method for the assessment of scale functioning than classical psychometric 
methods.  
The Rasch model (Rasch, 1960/1980) is a simple one parameter form of IRT with 
particularly strong mathematical characteristics. It offers the prospect of creating scales 
that meet fundamental measurement requirements providing the same measurement 
quality observed in the physical sciences (Luquet et al, 2001; Prieto et al, 2003; Tennant et 
al., 2004; Waugh and Chapman, 2005; Wright, 1996; Wright and Tennant, 1996). For this 
reason the Rasch model is the model applied throughout the body of my research.  
Despite these improvements in psychometric methods the most important component to 
creating accurate PRO measures is a thorough understanding and definition of the 
construct that is being measured. There has often been a lax approach to defining the 
constructs that researchers are trying to measure in PRO research. There are many 
examples in the field of PROs that are not based on any clear theory (McKenna, 2011; 
Gimeno-Santos et al, 2011). It is fundamental for accurate measurement to have a clear 
theoretical foundation as a starting point. This is essential to produce an outcome that is 
meaningful and purposeful.  
1.2 Aims of the thesis 
The thesis will consider ten publications and how each of these has contributed to 
knowledge in the field. Two important factors are considered in the work; the need for 
clear construct definition and the importance of rigorous psychometric approaches to 
measurement.  
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The specific aims of the thesis are: 
1. Describe methods of PRO development in relation to: 
a) PRO construct definition. 
b) Psychometric analysis. 
2. Evaluate the extent to which my own research has met these requirements. 
3. Critically assess the contribution of each study to the field. 
1.3 Structure of the thesis 
The first two chapters will discuss the importance of clear construct definition and 
psychometric measurement methods in PRO development. The articles included in the 
thesis will be categorised into groups and presented in Chapters 4-7. Due to restrictions in 
copyright, only the articles published in open access journals will be included. For the 
remaining articles, the abstract, DOI and URL will be provided. The thesis discusses each of 
the articles in relation to the specified methods. It also critically reviews the research to 
assess how the studies could have been approached differently or improved. Finally, 
Chapter 8 will summarise the work, consider areas for further study and suggest how my 
research will develop in the future. 
1.3.1 Chapter content 
Chapter 1: Introduction  
This chapter has provided an introduction to the topic and overview of the thesis. 
Chapter 2: Construct definition 
This chapter discusses the importance of clearly defining the construct that the PRO 
measures. 
Chapter 3: Psychometric methods 
In this chapter the quantitative methods for assessing the functioning of a PRO are 
considered. Two psychometric paradigms are discussed; CTT and IRT.  
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Chapter 4: Development of new PROs 
In this chapter three research studies are discussed in which new PRO measures were 
developed.  
Chapter 5: Application of PROs in international research 
This chapter discusses three studies relating to the application of PROs in international 
research. 
Chapter 6: Evaluation of existing PROs 
This chapter describes three studies which evaluate the psychometric properties of existing 
PROs.  
Chapter 7: Co-calibrating disease-specific PROs 
This chapter discusses future psychometric approaches to outcome measurement in which 
different disease-specific measures can be combined through a process of co-calibration. 
Chapter 8: Summary and Conclusions 
The final chapter summarises the research, shows how the research will develop in the 
future and provides conclusions. 
1.4 Chapter summary 
Accurate measurement is fundamental to the scientific process. The quality of 
measurement in PRO research has lagged behind that of the physical sciences. The thesis 
will discuss modern psychometric methods that are necessary to provide high quality 
measurement. It will focus on the importance of clear construct definition and the 
application of Rasch analysis. The thesis presents 10 articles relating to PRO development 
and application. Each article will be evaluated based on their contribution to the field and 
the quality of the methods employed. 
 
10 
 
Chapter 2: Defining the construct 
2.1 Introduction 
PROs are designed to measure constructs that are not directly observable (commonly 
described as latent variables). The constructs can cover a broad range of health outcomes. 
These include symptoms, functional limitations, health-related quality of life (HRQL), well-
being, participation and satisfaction with care. Whatever the type of outcome that a PRO 
assesses it is essential that a rationale and explanation of the construct is provided. This 
then forms a guide for the PROs content so that items representing the construct of 
interest can be selected. This chapter discusses the importance of clearly defining the 
construct and considers three approaches to construct definition. Each provides a different 
perspective in the construct definition process. Although there is a degree of overlap and 
commonality between the approaches it is not possible to explore this in detail in the 
present thesis. Instead, each will be discussed separately and their strengths and 
weaknesses considered.  
2.2 Background 
Several articles have been published detailing standards for the development of  PROs 
(Reeve et al, 2013; Erickson et al, 2009; Magasi et al, 2011; Revicki et al, 2000; Revicki et al, 
2007; Rothman et al, 2009; Snyder et al, 2011; Turner et al, 2007; US Food and Drug 
Administration, 2009). Most of these guidance documents identify the importance of 
having a clear conceptual basis for the PRO. Despite the existence of such guidelines a large 
number of outcome measures have been developed and continue to be developed without 
a clearly defined construct. For example, Nixon et al (2013) evaluated twenty six PROs 
available for epilepsy and concluded that none of the available measures had a clear 
conceptual basis.  
The consequences of failing to define the PRO construct clearly are serious (Rothman et al, 
2007). Without a clear definition the validity of the PRO must be questioned. Failure to 
define the construct properly often leads to the grouping of items that represent different 
kinds of outcome. For example, a PRO claiming to measure overall HRQL may confound 
items measuring symptoms (e.g. pain) with others measuring functioning or social impact. 
In the absence of clear construct definition erroneous interpretation of scores is likely as it 
is not clear what the scoring represents. This makes it difficult to assess the effectiveness of 
different interventions. Without proper construct definition accurate and purposeful 
measurement is not possible. Some of the approaches to PRO construct definition are 
examined in the next section. 
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2.3 Approaches to construct definition in PRO measurement 
Three approaches to defining the construct that a PRO measures will be discussed in this 
chapter. These are:  
- Theoretical underpinning: A theoretical grounding for the construct of interest 
should be provided. This places the measure within the context of a larger body of 
explanatory work. 
 
- Conceptual framework of the PRO: This approach explains the structure of the PRO 
and shows the relation between items, domains and the overall construct. It is 
usually organised in the form of a figure.  
 
- Measurement mechanism of the PRO: This is an approach to construct definition 
whereby the underlying mechanism of the measure is understood so that items can 
be manipulated to represent varying levels of the construct of interest.   
 
Each approach covers a slightly different component of construct definition. Figure 2.1 
shows how each of the approaches may relate in the construct definition process.     
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Figure 2.1: Approaches to defining the PRO construct 
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2.4 Theoretical underpinning 
The constructs to be measured should be embedded in a larger body of theoretical work. 
This gives each construct a greater degree of explanation and allows the construct to be 
understood relative to other variables important in the patients’ disease.  
Scientific theories have been described as nets cast to catch what we call ‘the world’: to 
rationalise, to explain, and to master it (Popper, 1963). They are developed through 
scientific methods including hypothesis generation and testing, deductive and inductive 
logic and parsimony (Gauch, 2002). They are used to represent scientific knowledge.  
One of the most influential explanations of the properties of scientific theories has been 
provided by Popper (1959). He identified the following characteristics: 
1.  Theories should include causal explanations; from these explanations it is possible to 
make specific predictions. 
2. A theory should have the property of falsifiability; the specific predictions that the theory 
includes should be testable and therefore falsifiable.  
The most important aspects of a scientific theory are its testability and falsifiability (Popper, 
1963). This allows the content to be scrutinised scientifically. A theory that is not refutable 
cannot be considered a true scientific theory. More specific theories lead to clearer 
predictions and more testable content.  
Placing a construct in a wider explanatory theory considerably strengthens the conceptual 
foundation of a construct. The needs-based approach to quality of life (QoL) provides an 
example of how this can be achieved (Hunt and McKenna, 1992).  This is the approach used 
in some of my own research presented in the following chapters. It is built on theoretical 
work on human needs (Maslow, 1970; Max-Neef et al, 1991; Kenrick et al, 2010). According 
to the theory QoL is high when needs are fulfilled and low when they are not. Relevant 
needs can be seen to fall into several different categories including those related to safety 
and security, socialisation, affection, esteem, cognition and personal development. 
Different illnesses impact on patients’ ability to meet their needs in different ways.  
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The needs-based approach also defines and explains the relation with other constructs 
relating to the impact of disease. QoL is clearly distinguished from the constructs of 
impairments and activity limitations. These latter types of outcome may influence QoL but 
are only important to the patient insofar as they prevent need fulfilment.  Figure 2.2 shows 
a simplified model of the interrelations between impairments, functional limitations and 
needs-based QoL (McKenna and Doward, 2004). It also shows how other factors such as 
personality and culture may influence overall QoL.  
 
Figure 2.2: Influences on QoL 
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2.5 Conceptual frameworks 
In addition to explaining the wider theoretical context for a construct it is also important to 
identify what a PRO actually measures in terms of content. A common approach to 
construct definition is to use conceptual frameworks for this purpose.  The conceptual 
framework should provide an explanation of the concepts measured and the relations 
between the concepts. It should also show how each item relates to the concepts. The 
conceptual framework is usually represented figuratively (FDA, 2009; Erickson et al, 2009).  
Erickson et al (2009) have attempted to guide the development of conceptual frameworks 
likening them to hierarchies of increasing complexity. At a very basic level there are single 
items. These can then be grouped into specific or generic families at a higher order. Above 
this level are more complex aggregate or compound concepts composed of multiple 
families. This PRO concept taxonomy provides the structure for a PRO. Figure 2.3 below 
shows an example conceptual framework based on the Cambridge pulmonary 
hypertension outcome review (CAMPHOR) activities limitations scale (McKenna et al, 
2006). Activity limitation is defined by six different kinds of activities (e.g. walking). Below 
this level single items are used to measure the activity kinds (e.g. walking a short distance; 
walking up a slight incline). This approach clearly represents how the different kinds of 
activities relate to the overall construct.  
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Figure 2.3: Conceptual framework for activity limitations in pulmonary hypertension 
 
Conceptual frameworks are primarily concerned with explaining the inter-relations 
between items and domains of a PRO. Although they are useful in guiding PRO 
development they are also limited in their scope as they are descriptive rather than 
explanatory and may leave some parts of the construct unsolved (Donatti et al, 2008). For 
example, a HRQL framework may identify several different domains and how items relate 
to the domains. However, it may fail to explain why the domains have been chosen and 
how these relate more broadly to the persons health. Without this further explanation ill-
conceived domains may be chosen that lack validity.  
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2.6 Measurement mechanism of the construct 
Recent research has suggested that it is important to explain exactly ‘how’ a measure 
works and why the items represent different levels of the construct of interest (Stenner et 
al, 2013). To do this it is necessary to understand the measurement mechanism of the 
construct.  
The approach most frequently used in health outcome measurement assumes that the 
items in a scale are manifestations of the construct (latent variable) (Stenner et al, 2008). 
When changes occur in the latent variable it is assumed that this will be shown in the item 
responses. This principle is shown in Figure 2.4. The problem with this approach is that the 
items may appear to be related to the construct but it is not clear exactly how they are or 
why the items represent different levels of the construct. To achieve this a causal 
explanation of the mechanism is needed.  
 
Figure 2.4: General psychometric explanation for a latent variable 
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Stenner et al (2013) argue that the construct should be explained by a specification 
equation. For example, in the physical sciences force is defined by acceleration and mass. 
By manipulating one of the variables a predictable change in force should be observed. In 
relation to outcome measurement in the social sciences, it is argued that manipulations of 
specific aspects of items should result in predictable changes in the level of construct 
measured. By finding these aspects it is possible to provide a measurement specification 
equation similar to that in the physical sciences. In the absence of this kind of specification 
equation the construct cannot be fully understood. Measures without an explanatory 
measurement equation have been likened to ‘black boxes’ where a construct may be 
understood and explained loosely but not fully.  
These ideas have been shown clearly in a body of work leading to a model of reading ability 
(Stenner et al, 2013). The measurement specification equation has been defined by the 
authors by the two variables text complexity and sentence length. An increase in one or 
both of these variables will increase the difficulty of the text. Using this method all texts 
can be graded with a ‘lexile’ score. This work has led to widespread adoption of this scoring 
system for assessing children’s progression with reading ability in the US.     
The application of this approach has so far been limited to a few areas of research by the 
original authors. The approach has the potential to markedly improve the precision of 
measurement in health research. Despite the potential no outcomes are available that 
have adopted this approach in health research. However, it has been included in the thesis 
to provide an alternative perspective and to help evaluate the research included. 
2.7 Chapter summary  
This chapter has discussed three approaches to construct definition. Each of the 
approaches focuses on a different aspect of construct definition. Scientific theories provide 
in depth explanations about the nature of constructs. Embedding the construct definition 
of a PRO within a scientific theory strengthens it considerably. Conceptual frameworks 
provide useful and simple explanations of the inter-relations between items, domains and 
the constructs of a PRO. An alternative approach to this is to identify a specification 
equation for the construct so that it is possible to explain exactly how the measure works.  
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Chapter 3: Psychometric methods 
3.1 Introduction 
In this chapter quantitative methods for assessing the functioning of a PRO will be 
discussed.  
Two main psychometric paradigms are available for this purpose: 
1. Classical test theory analysis 
2. Item response theory 
3.2 Classical test theory 
3.2.1 Introduction 
Until the 1990’s classical test theory (CTT) was the dominant paradigm in the statistical 
evaluation of PROs. This approach is based on true score theory (Allen and Yen, 2002; 
Novick, 1996; Traub, 1997). The approach assumes that a person has a ‘true score’ or an 
accurate score that represents their real level/ability on a test. However, this true score is 
also obscured by error that is inherent in the test. The observed score is expressed in the 
following way (Kline, 2005): 
Observed score = True score + error 
Classical psychometric approaches attempt to explain the relation between these variables. 
In terms of scale construction, important methods within this framework include 
assessments of reliability and factor analysis (Allen and yen, 2002; Pett et al, 2003). Both 
methods are based on correlational analyses.  Reliability is defined as the degree of 
consistency of a scale. Various forms of reliability assessment are available and their use 
within scale development aims to reduce the level of unexplained error inherent in a scale. 
Factor analysis is used to explore the inter-relations between items in order to group the 
items into smaller sets of explanatory dimensions or factors.       
A brief description of some of the classical psychometric approaches to scale development 
is provided below. 
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3.2.2 Reliability 
Approaches to the assessment of reliability fall into two main categories: internal reliability 
and test-retest reliability (reproducibility).  
3.2.2.1 Internal reliability 
Internal reliability is usually assessed using Cronbach’s alpha coefficients (Cronbach, 1951) 
as a means of assessing the extent to which the items in a scale are inter-related. 
Traditionally, a low alpha (below 0.7) is taken to indicate that the items do not work 
together to form a scale (Nunnally and Bernstein, 1994).  
However, this form of assessment has come under criticism for several reasons. It is well 
known that it can be artificially inflated by selecting items that are homogeneous (Hattie, 
1985; Barchard and Hakstian, 1997; Raykov, 1997). This means that items at the extreme of 
a scale, which may be important for increasing the measurement range and precision of 
the instrument, may be discarded due to lower item-total correlations.  Cronbach’s alpha 
can also be increased by simply increasing the number of items in a scale (Nunnally and 
Bernstein, 1994; Streiner, 2003). These findings indicate that this form of reliability should 
be interpreted with caution as it is prone to bias. 
3.2.2.2 Test-retest reliability 
The test-retest reliability of a measure is an estimate of its reproducibility over time when 
no change in condition has taken place. It is assessed by correlating scores on the scale 
obtained on two different occasions. A high correlation indicates that the instrument 
produces a low level of measurement error.  
Various statistics are used for the correlation analysis including Pearson correlation 
(Pearson, 1895), Spearman’s rank correlation (Spearman, 1904) and intra-class correlation 
(ICC) (Koch, 1982). Some have argued that ICC is more appropriate for the assessment of 
reliability as, unlike Pearson correlation, it takes into account both within-subject change 
and systematic change in mean (Lexell and Downham, 2005). However, Spearman’s rank 
correlation is the most appropriate for PRO data as they are ordinal in nature. 
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There is no widely accepted consensus on what the minimum level of reliability of a test 
should be. It has been argued that a minimum Pearson value of 0.85 should be used 
(Streiner and Norman, 1989). This is because the level of explained variance in scores is the 
square of the correlation value. This means a correlation value of 0.85 represents 72% 
explained variance. Conversely 28% of variance in scores is unexplained. The level of 
unexplained variance increases sharply as the correlation coefficient decreases.  
3.2.3 Factor analysis 
Factor analysis includes a group of statistical methods that are used to identify the relations 
between a set of variables or questionnaire items in order to group them into a smaller 
number of explanatory domains (Nunnally and Berstein, 1994). It is often used in 
instrument development in order to investigate the internal structure of the construct of 
interest.  
There are two basic forms of factor analysis: exploratory and confirmatory factor analysis 
(Pett et al, 2003). Exploratory factor analysis is used when there is uncertainty regarding a 
construct. It attempts to find relations between items in order to define the construct. 
Confirmatory factor analysis is used when there is an existing hypothesis regarding the 
structure of a construct. It is used to assess how well a set of data fit this hypothesized 
construct.  
The initial steps in a factor analysis are performed using Pearson product moment 
correlations. Many of the assumptions of the Pearson correlation are therefore applicable 
to factor analysis including the requirement for large sample sizes, normality of 
distributions and linear relationships between items (Pett et al, 2003).       
Factor analysis has been criticised on several grounds. It involves a series of different 
statistical approaches and there is no consensus on which method is the most appropriate 
to use. For example, in the SPSS statistical package (IBM Corp, 2011), for exploratory factor 
analysis there are seven options for the ‘extraction method’, six options for the ‘rotation’, 
and also ‘covariance’ and ‘correlation matrix’ approaches leading to 84 different options for 
the analysis (Christenesen et al, 2012). Different approaches may lead to different results. 
Therefore, there is a large degree of subjectivity and ‘artistry’ involved in the method. 
Furthermore, misinterpretation of results is common (Pett et al, 2003).  
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The major limitation of the approach though is that factor analysis provides little 
information regarding the functioning of the measurement properties of a scale 
(Christensen et al, 2012; Wright, 1996). It does not inform on the hierarchy of items in 
terms of their difficulty. Neither does it inform on whether a scale meets the requirements 
of interval level measurement. No formal assessments of these properties are available 
within the factor analysis framework. In fact one of the assumptions of the approach is that 
there is already a linear relation among the items.  
3.2.4 Limitations of CTT  
The main advantages of CTT are that it is based on relatively weak assumptions and it 
requires little mathematical knowledge on the part of the user (De Champlain 2010). This 
means the methods are easier to use and more accessible to developers of new PROs.  
Several limitations of the methods employed in CTT have been discussed above. In addition 
to these, CTT has been criticised on several levels due to its weak underlying assumptions 
(Petrillo et al, 2015; Xitao, 1998; Hambleton et al, 1991). True scores in the population are 
assumed to be measured at the interval level and normally distributed. However, PROs 
provide ordinal measurement and data are often not normally distributed. CTT also 
produces findings that are both sample and scale dependent. This is problematic as the 
measurement performance of a scale can be distorted by the sample it is drawn from.  
CTT methods of PRO development provide ordinal level measures that should not be used 
in parametric assessments (Tennant et al, 2004). Parametric analyses provide more 
powerful and complex analyses than their non-parametric counterparts. They include the 
use of change scores in clinical trials, regression and analysis of variance statistics. 
Unfortunately the data requirements are usually ignored by most researchers using PRO 
measures leading to unknown consequences for study results.  
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3.3 Item response theory 
3.3.1 Introduction to item response theory  
Item response theory (IRT) includes a group of models that are concerned with the design, 
analysis and scoring of tests. Mathematically they are more sophisticated than their CTT 
counterparts and are primarily focused on item rather than test-level information. Unlike 
simpler CTT approaches, IRT does not assume that each item is equally difficult. Instead it 
views each item as representing a different level of the construct. IRT models the response 
of patients of a given ability to an item of a given difficulty (or severity of health outcomes).  
In IRT the probability of a given response is a mathematical function of the person and item 
parameters. The person parameter is the latent trait being measured (for example 
functional disability). Several different parameters may be included at the item level. The 
number of parameters here defines the type of IRT approach (Chong, 2013). Item 
parameters may include item difficulty, discrimination and guessing. Correspondingly these 
would represent one, two or three parameter models.       
The method adopted in my own research is the Rasch model (Rasch, 1960/1980). The 
Rasch model is a simple logistic one parameter IRT model. It differs importantly from other 
IRT models in terms of its approach to measurement (Andrich, 2004). Other IRT models 
focus on attempts to find a model that fits the data. In contrast the Rasch approach focuses 
on whether data fit the Rasch model. The Rasch model has a number of special properties 
that make it particularly strong in terms of measurement. This is discussed in the following 
section.   
3.3.2 The Rasch model 
The Rasch model may be conceived of as a probabilistic version of the Guttman scale 
(Guttman, 1950). According to the Rasch model, the probability that an individual will 
respond in a certain way to a particular item is a logistic function of the relative distance 
between the item location parameter and the person location parameter. This difference 
governs the probability of the expected response for a person, of a given ability, to an item 
of a given severity. In other words, the probability of a person affirming an item depends 
on how much a person is affected and the severity of the item. 
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The simplest Rasch model is the dichotomous model and can be formalised in the following 
way (Rasch, 1960/1980): 
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= θ
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θ  
Where )(θip  is the probability that persons with ability (severity) θ will affirm item i, and 
b is the item difficulty parameter. 
 
3.2.3 Advantages of the Rasch model 
The Rasch model was selected in my own research due to its special mathematical 
properties, in particular, its satisfaction of fundamental measurement requirements 
(Tennant et al, 2004; Wright, 1997). When items fit the model they possess a number of 
characteristics including criterion-related construct validity, unidimensionality, additivity, 
specific objectivity and sufficiency. The characteristics of specific objectivity and sufficiency 
are requirements of fundamental measurement and the Rasch model is the only form of 
IRT that achieves this.   
For a measure to achieve specific objectivity in relation to the latent construct, comparison 
between two persons should be independent of the test or particular set of items selected 
from the test that are chosen for the comparison (Stenner, 1994). The property of 
sufficiency means that the person score on the scale contains all the available information 
within the specified context about the individual (Linacre, 1992). 
The special properties of the Rasch model means it can be considered a gold standard for 
measurement in the health sciences. When data fit the model interval measurement can 
be achieved.  
3.3.2.4 Fit to the Rasch model 
The study of Rasch model fit is a process where no individual fit statistic is either necessary 
or sufficient to confirm the model (Andrich, 1988; Andrich and Sheridan, 2009). Therefore, 
the final interpretation of fit is a collective one based on several indices. If satisfactory fit is 
achieved across this range of different indices then a scale can be considered to show fit to 
the Rasch model. Different statistical packages provide different fit statistics. The fit 
statistics described below are available using RUMM2030 package (Andrich and Sheridan, 
2009). 
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3.3.2.4.1 Person separation index (PSI) 
Internal reliability is analysed using the PSI. The PSI is indicative of the power of the items 
to distinguish between respondents. A PSI score of 0.70 is the minimum acceptable level.  
3.3.2.4.2 Item level fit and overall fit 
Individual item fit statistics are investigated via Chi
2
 fit statistics. A significant Chi
2
 fit 
statistic (p < 0.05 (Bonferroni adjusted)) indicates a significant deviation from model 
expectations. Individual item fit residuals are also investigated. These fit residuals are the 
standardised sum of the squared residuals. These should fall within ±2.5 if all individuals 
respond in the anticipated way. High negative residuals are indicative of item redundancy 
and high positive residuals multidimensionality. 
The overall scale fit to the model is examined by reference to several indices.  An overall 
item-trait interaction Chi
2
 fit value is calculated based on item level statistics. A significant 
Chi
2
 statistic (p < 0.05) indicates that there is a real deviation of the scale from the expected 
pattern and a lack of fit to the Rasch model. Overall fit of the data is also investigated via 
Item and Person interaction statistics. These assessments measure the extent to which 
observed item and person estimates deviate from the expected. The mean location of the 
items is always anchored at 0. Within this function both Person fit residual and Item fit 
residual statistics are transformed by RUMM to approximate Z-scores; representing a 
standardised normal distribution. When the data fit the model the overall distribution 
statistics for Item fit and Person fit should have a mean of approximately 0 and a standard 
deviation of approximately 1. 
3.3.2.4.3 Differential item functioning (DIF) 
A requirement of the Rasch model is that items should be invariant across groups. This is 
investigated through tests of DIF. DIF represents instability in the order of severity of items 
and indicates that the scale may not work in the same way in different sub-groups of 
individuals (such as those defined by age or gender) that share the same level of trait being 
measured (Holland and Wainer, 1993). An ANOVA of standardised residuals is carried out 
to examine DIF by relevant groups.  
 
26 
 
3.3.2.4.4 Targeting of the measure 
Targeting of items to the respondents can also be assessed by examining person-item 
distribution graphs. These show the ordering of both persons and items on the same logit 
scale and indicate whether the items in the scale are well matched to the respondents. This 
can help to identify where additional items are required to improve measurement along 
the latent-trait. 
3.3.2.4.5 Functioning of the response options 
The Rasch model allows formal assessment of the functioning of the response options of 
the measure. The probability of each response being endorsed should increase logically as 
the level of trait exhibited by the persons increases. The point between two adjacent 
categories (where the probability of endorsing either reaches 0.5) is called the threshold. 
For data to fit the model the threshold points should be correctly ordered so that persons 
are more likely to select the responses in the logical order. Participants with higher levels of 
trait would also be more likely to select the response categories representing high level of 
trait (and vice versa). Disordered response thresholds occur when participants have 
problems discriminating between different response categories.      
3.3.2.4.6 Local dependency 
One of the requirements of the Rasch model is the local independence of items. Local 
dependency occurs when items are too closely related such that the response to one item 
has too strong an influence over answers to another item (Tennant and Conaghan, 2007; 
Baghaei, 2008). The practical impact of this is a spreading of the Rasch estimates as they 
become slightly more predictable (Baghaei, 2008). Correlation of the residuals (after the 
underlying trait is conditioned out) should therefore be close to 0.  
3.4 Chapter summary 
CTT has been the dominant force in the statistical evaluation of PROs. Although simple and 
practical to use these methods have weak underlying assumptions. In addition, the 
methods provide only limited, ordinal level data. 
IRT is built on more robust assumptions than CTT. The Rasch model is a one parameter 
form of IRT with particularly strong mathematical properties. When data fit the Rasch 
model then fundamental measurement is achievable. For this reason the Rasch model has 
been given preference in the work presented in this thesis.   
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Chapter 4: Development of new PROs 
4.1 Introduction and articles 
This chapter discusses three articles describing the development of new PROs. Each study 
describes the development of a new disease-specific PRO and used the same development 
methods. The conceptual basis and measurement approach used in each study is discussed. 
Finally the methods used are evaluated in terms of their suitability.     
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4.1.1 Article 1: The development of patient-reported outcome indices for 
multiple sclerosis (PRIMUS) 
 
Doward LC, McKenna SP, Meads DM, Twiss J, Eckert BJ. The development of patient-
reported outcome indices for multiple sclerosis (PRIMUS). Mult Scler. 2009 Sep;15(9):1092-
102. doi: 10.1177/1352458509106513. 
 
BACKGROUND: Complex diseases such as multiple sclerosis (MS) present dilemmas over 
the choice of patient-reported outcome measures as no single scale can inform on all types 
of MS impact from the patient's perspective. OBJECTIVE: To develop an outcome tool, the 
Patient-Reported Indices for Multiple Sclerosis (PRIMUS), to assess MS symptoms, 
activities, and quality of life. 
METHODS: PRIMUS content was derived from qualitative interviews with UK MS patients 
and checked by clinical experts. Semi-structured cognitive debriefing interviews assessed 
scale face and content validity. PRIMUS scaling properties, reliability, and construct validity 
were assessed by a test-retest postal survey.  
RESULTS: Cognitive debriefing interviews (n = 15) demonstrated scale clarity, relevance, 
and comprehensiveness. The postal survey was completed by 135 patients with MS. After 
removal of misfitting items and those exhibiting differential item functioning, all scales 
fitted the Rasch model, confirming unidimensionality. For all scales, test-retest reliability 
exceeded 0.80. Scale scores were related to perceived MS severity, general health, and 
symptoms of depression. Moderate correlations were observed between PRIMUS and 
Nottingham Health Profile scores.  
CONCLUSIONS: Clinicians and researchers can have confidence in scores obtained by 
respondents on the PRIMUS. The PRIMUS will aid the assessment of the impact of MS from 
the patient's perspective. 
 
The article is available via: http://msj.sagepub.com/content/15/9/1092.long 
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4.1.2 Article 2: The development and validation of the Unidimensional 
Fatigue Impact Scale (U-FIS) 
 
Meads DM, Doward LC, McKenna SP, Fisk J, Twiss J, Eckert B. The developmentand 
validation of the Unidimensional Fatigue Impact Scale (U-FIS). Mult Scler.2009 
Oct;15(10):1228-38. doi: 10.1177/1352458509106714. 
 
BACKGROUND: The multidimensional assessment of fatigue is complicated by the 
interrelation of its multiple causes and effects. 
OBJECTIVE: The purpose of the research was to develop a unidimensional assessment of 
fatigue (U-FIS). 
METHODS: Data collected with the Fatigue Impact Scale (FIS) were subjected to Rasch 
analysis to identify potential problems with the scale. Additional items for the U-FIS were 
generated from interviews with UK MS patients. The U-FIS was tested for face and content 
validity in patient interviews and included in a validation survey to determine 
dimensionality (Rasch model), reliability and validity. 
RESULTS: The original FIS was not unidimensional when subscale items were combined. The 
modification of the FIS and addition of a number of items allowed the development of a 22-
item unidimensional scale (U-FIS) that was reliable (Cronbach Alpha = 0.96; test-retest = 
0.86,) and valid given correlations with the Nottingham Health Profile and ability to 
distinguish between MS severity groups. There was no significant difference in U-FIS scores 
according to MS type. 
CONCLUSION: It is valid to conceptualize the functional impact of fatigue as 
unidimensional. The U-FIS is a reliable and valid questionnaire that will allow the 
measurement of this construct in clinical studies. 
 
The article can be accessed via: http://msj.sagepub.com/content/15/10/1228.long 
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4.1.3 Article 3: Development and validation of the living with chronic 
obstructive pulmonary disease questionnaire 
 
McKenna SP, Meads DM, Doward LC, Twiss J, Pokrzywinski R, Revicki D, Hunter CJ, 
Glendenning GA. Development and validation of the living with chronic obstructive 
pulmonary disease questionnaire. Qual Life Res. 2011 Sep;20(7):1043-52. doi: 
10.1007/s11136-011-9850-6. 
 
PURPOSE: Available patient-reported outcome (PRO) measures for chronic obstructive 
pulmonary disease (COPD) focus primarily on impairment (symptoms) and activities 
(functioning). The purpose of the study was to develop a patient-based PRO measure for 
COPD that captures the overall everyday impact of living with COPD from the patient's 
perspective. 
METHODS: LCOPD items (Living with COPD Questionnaire) were generated from qualitative 
interviews in the U.K. and focus groups in the U.S.A. The draft measure was tested for face 
and content validity in both countries. Item reduction and testing for reproducibility and 
construct validity was conducted via Rasch and traditional psychometric analyses. 
RESULTS: The draft LCOPD was found to be relevant and acceptable to patients in the U.K. 
(N = 19) and U.S. (N = 16). Application of Rasch analysis to data collected in validation 
studies (n = 162 in the U.K. and 145 in U.S.) identified  a 22-item scale that measured a 
single construct in both countries. Psychometric  analyses indicated that this version was 
internally consistent and reproducible.  Scores on the measure were related as expected to 
clinician ratings of disease severity and patient ratings of COPD severity and general health. 
CONCLUSIONS: The LCOPD is a new measure examining the everyday impact of living with 
COPD. It demonstrates good scaling properties and may prove valuable in understanding 
treatment benefits. 
The article cab be accessed via: http://link.springer.com/article/10.1007%2Fs11136-011-
9850-6 
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4.2 Description of articles 
The Patient Reported Outcome Indices for Multiple Sclerosis (PRIMUS; Doward et al, 
2009b) was developed due to the lack of high quality measures available for the 
assessment of the holistic impact of MS from the patients’ perspective. Other available 
outcome measures such as the Multiple Sclerosis Quality of Life questionnaire (MSQoL-54; 
Vickrey et al, 1995) and Multiple Sclerosis Impact Scale (MSIS-29; Hobart et al, 2001) 
predominantly measure symptoms and functioning. The PRIMUS contains three scales 
measuring; symptoms, activity limitations and needs-based quality of life (QoL). Each scale 
showed good fit to the Rasch model. In addition, all scales had adequate levels of internal 
reliability (Cronbach’s alpha >0.70) and test-retest reliability (Spearman Rank >0.80). All 
scales distinguished between self-perceived severity and symptoms of depression providing 
evidence of construct validity.   
The Unidimensional Fatigue Impact Scale (U-FIS) was developed as a unidimensional 
measure of the impact of fatigue from the patients’ perspective (Meads et al, 2009). 
Fatigue is one of the main symptoms of Multiple Sclerosis and has a major impact on the 
patient’s life (Multiple Sclerosis Society UK, 1997; Freal et al, 1984; Multiple Sclerosis 
Council for Clinical Practice Guidelines, 1998; Krupp et al, 1988). It has often been 
conceptualised as a multidimensional construct including sub-components such as motor 
and cognitive fatigue (Schwid et al, 2002; Trojan et al, 2007). However, attempts to define 
fatigue as a multidimensional construct have been challenging due to the multiple causes 
of fatigue and the inter-relations between the different ‘types’ of fatigue (Penner et al, 
2007).  
Measures available for assessing fatigue include the fatigue severity scale (Krupp et al, 
1989), The Multi-dimensional Fatigue Inventory (Smets et al, 1995), and the Fatigue Impact 
Scale (FIS; Fisk et al, 1994). Each of the available measures conceptualises fatigue as a 
multidimensional construct and were developed without the benefit of modern IRT 
methods. The aim of this study was to investigate whether a unidimensional measure of 
fatigue specific to multiple sclerosis patients could be developed. The content of the new 
measure was based partly on the content of the FIS and also on patient interviews. The 
final scale fit the Rasch model supporting the unidimensional structure of the measure. 
Adequate internal reliability (Cronbach’s alpha=0.96), test retest reliability (Spearman’s 
rank=0.86) and construct validity (scores significantly related to self-perceived severity and 
current MS flare up) was also observed.  
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The Living with Chronic Obstructive Pulmonary Disease (LCOPD) Questionnaire (McKenna 
et al, 2011) was developed as a disease-specific needs-based QoL measure. A 
comprehensive review identified several generic and disease-specific outcome measures 
for COPD (McKenna et al, 2011). However, very few of these measures covered issues 
related to the emotional or quality of life impact of the disease and, where they did, they 
were covered by only a handful of items. Due to this, it was decided to develop an outcome 
measure for this purpose. The measure was developed simultaneously in the UK and US. 
The final measure had good fit to the Rasch model in both centres. In addition, good 
internal reliability (Cronbach’s alpha in UK and US = 0.92) and test-retest reliability 
(Spearman’s Rank UK = 0.89; US=0.83) were observed. The scale also distinguished 
significantly between self-perceived severity and clinician-perceived severity.    
Samples of the PRIMUS, U-FIS and LCOPD are provided in Appendices 2-4. The full 
measures are held under copyright and can be obtained from gr@galen-research.com.  
4.3 Methodology 
In each of the three studies appropriate ethics approval was sought. Informed consent was 
obtained from all of the participants in the studies. All data obtained from the participants 
was anonymised.  
The development process for all the measures involved three stages: 
1. Qualitative interviews and analysis to generate item content.  
2. Item reduction and assessment of the psychometric properties of the scales. 
3. Cognitive debriefing interviews. 
4.3.1 Qualitative interviews  
In the PRIMUS and U-FIS studies thirty relevant patients were included in the qualitative 
interviews. In the LCOPD study thirty patients were included in one-to-one interviews in 
the UK and 14 patients attended two focus groups in the US. The qualitative data formed 
the basis of the content for the PROs. As PROs are used to inform on the patient-perceived 
impact of an illness it is fundamental that the patient is involved.  
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Content analysis was conducted by the research team as a whole. The transcripts were first 
read by two researchers to extract issues relating to the constructs. These were then 
collated and coded thematically by the research team. The coding was guided by the 
relevant conceptual background for each measure. Finally, the themes identified were 
reviewed by the research groups and harmonised.    
4.3.2 Item reduction and assessment of psychometric properties 
A test-retest psychometric survey was conducted in each of the studies. This involved 
relevant patients completing the draft measures at two time points two weeks apart. In 
addition, patients also completed a comparator measure and questions about their overall 
health and disease.  The purpose of the surveys was to identify scales that were 
unidimensional with good measurement properties. Item reduction was conducted using 
Rasch analysis. In addition, internal reliability, test-retest reliability and construct validity 
were assessed.  
4.3.3 Cognitive debriefing interviews 
Cognitive debriefing interviews were conducted to test the content and face validity of the 
draft measures. These interviews were designed to assess the clarity, relevance and 
comprehensiveness of the measure. The measures were completed by relevant patients in 
the presence of one of the developers and the interviewees asked about the ease of 
completion and the appropriateness of the instructions, items, and response formats. 
Items found to be problematic were considered for removal. 
4.4 Evaluation 
The development of the three measures was successful and each offers an important 
improvement to the assessment of outcome within their disease areas. The measures 
showed good psychometric properties across a range of analyses. All of the measures 
showed good fit to the Rasch model showing the measures were unidimensional and had 
good measurement properties. Classical Test Theory (CTT) analyses confirmed low levels of 
random measurement error. In addition, all scales were able to distinguish between known 
groups showing evidence of construct validity. 
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4.4.1 Construct definition 
The PRIMUS QoL scales and the  LCOPD take the needs-based approach to QoL as their 
conceptual basis. The needs-based approach to QoL is the most widely implemented 
approach to QoL and differs importantly from measures of Health Related Quality of Life 
(HRQL) (McKenna, 2011). HRQL measures are usually index based outcomes with varying 
numbers of domains representing different aspects of the impact of the disease on the 
patient. They predominantly measure symptoms and functional limitations with just a few 
items measuring the impact of these on the patient’s life. In contrast the needs-based 
approach to QoL conceptualises quality of life as a unidimensional construct. 
The needs-based approach to QoL is embedded within the wider body of theoretical work 
on human motivation (Maslow, 1970; Max-Neef et al, 1991; Kenrick et al, 2010). The 
approach postulates that individuals are driven by their needs and that fulfilment of their 
needs provides satisfaction. Quality of life is high when more needs are fulfilled and lower 
when they are less able to meet their needs. Chronic diseases impact on the patients’ QoL 
by limiting their ability to meet their needs. Each disease impacts on patients’ ability to 
meet their needs in different ways.  
The purpose of the patient interviews in each disease is to identify how that particular 
illness limits patients’ ability to meet their needs. Information from the interviews is used 
to develop a conceptual framework for the PRO. This includes all of the themes identified 
and shows how these relate to the patients’ needs. During the psychometric evaluation 
stage care is taken to ensure that the content of the PRO is refined without compromising 
its conceptual basis.         
The conceptual basis of the symptoms and activity limitations scales of the PRIMUS are 
based on the World Health Organization’s (WHO) classification of impairments 
(physiological and anatomical) and activity limitations (capacity and performance) (World 
Health Organisation, 1980; 1999). This classification system provides a detailed description 
of different types of impairments and functional limitations. It also describes the 
relationship between these and other outcomes. The classification system gives a level of 
detail that allows very specific hypotheses to be generated from its content, meaning it 
fulfils much of the criteria necessary for a theory (Popper, 1959). WHO defines impairments 
as loss or abnormality of psychological, physiological or anatomical structure or function, 
which represents disturbances at the level of the organ. Activity limitation (functioning) is 
defined as any restriction or lack of ability to perform an activity in the manner or within 
the range considered normal for a human being.   
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The U-FIS was based on the original Fatigue Impact Scale (Fisk et al, 1994). The FIS is a 40-
item questionnaire consisting of three sub-scales assessing the impact of perceived fatigue 
on; cognitive functioning (10 items), physical functioning (10 items) and psychosocial 
functioning (20 items). Due to the strong inter-relations between the different causes of 
fatigue and the problems in identifying sub-domains with any clinical validity the U-FIS 
aimed to capture the overall impact of fatigue as a unidimensional construct (Penner et al, 
2007). The conceptual basis of the final measure was again based on the WHO classification 
of impairments (physiological and anatomical) and activity limitations (capacity and 
performance) (World Health Organisation, 1980; 1999). The U-FIS is a summary measure of 
the patient-perceived impact of MS-related fatigue on functional capacity. Consequently, it 
measures the construct of patient-perceived fatigue-related functional impairment. The 
scale is not designed as an objective or clinical measure of fatigue symptoms.  
Although all scales have specified conceptual foundations they are also somewhat limited 
in their definitions. As discussed in chapter 2, recent research has attempted to identify the 
underlying measurement mechanism of the construct (Stenner et al, 2013). By providing 
this it would be possible to explain ‘how’ the measures work. This would mean it would be 
possible to identify the characteristics of the items that make them represent different 
levels of the construct.  
4.4.2 Psychometric methods 
Although all studies provided evidence of construct validity, additional assessments of 
validity would be also desirable. For example, it was not possible to show evidence of the 
responsiveness of the scales within the studies. Further studies to assess responsiveness 
are necessary.    
The Rasch model was used for item reduction in all of the studies. All of the final scales 
showed good fit to the model. This means that it is possible for the measures to achieve 
fundamental measurement. This provides a major advance in measurement in these 
disease areas. 
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Despite this some limitations in the methods are worthy of discussion. Methods for 
assessing fit to the Rasch model evolve over time as knowledge about model requirements 
is developed. For example, one of the requirements of the Rasch model is local 
independence of the items. This means items should not be too closely related such that 
the response to one item has too strong an influence over answers to another item 
(Tennant and Conaghan, 2007; Baghaei, 2008). It is assessed by identifying items with high 
residual correlations (after the underlying trait is conditioned out). Correlations should be 
close to 0. However, there is no clear criterion for identifying high residual correlations. 
When the scales above were developed a criterion of identifying residual correlations of > 
0.3 was used (Tennant and Conaghan, 2007). However, more recently this has been 
challenged and researchers have argued that this is too lenient and that any correlation 
value > 0.2 above the average correlation should be used (Christensen et al, 2013). By 
changing the criteria in this way more evidence of local dependence may have been 
observed than originally identified. This could have affected the items selected for the 
measure. In order to overcome this problem scales would need to be continuously re-
assessed as new knowledge is gathered. There are obvious practical limitations in how 
frequently this could be done.   
The sample sizes available for Rasch analysis in each study were: PRIMUS, n=135; U-FIS, n = 
135; LCOPD UK, n = 162, US, n = 145. As with other statistical analyses, small sample sizes 
produce less precise and robust estimates and less powerful fit analyses (Linacre, 1994). 
The sample sizes in each of the studies were large enough to provide 99% confidence that 
item locations were stable within 0.5 logits (Linacre, 1994). Although this provided a good 
level of accuracy for the analyses it may be argued that larger samples providing a higher 
degree of accuracy are necessary for scale development. A sample of size of two hundred 
and fifty patients or more would give a ‘high stakes’ level of accuracy (Linacre, 1994). 
Unfortunately, accessing this number of patients in health research is often challenging as 
many diseases affect only a small proportion of the population.              
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Finally, only one patient sample was used for the psychometric analyses in each study. As 
the psychometric study was used to reduce the item pool it means that several items were 
removed during the analyses. Ideally, a second psychometric study should have been 
conducted in which the functioning of the scale was assessed using the final item set only. 
This would confirm that the measure works appropriately without the additional items. 
Due to the challenge of recruiting such large numbers of patients it was not possible to do 
this. Further studies should be used to confirm the measurement properties of the scales 
using the final set of items only.   
 
4.5 Chapter summary 
The three articles included in this chapter each describe the development of new disease-
specific PROs. The new measures provide important advancements in outcome 
measurement in their relevant disease areas. The studies showcase a well-developed 
standardized methodological approach to PRO development.  All of the scales had a clear 
conceptual foundation and showed good fit to the Rasch model.   
Some limitations of the research were identified. Further work is necessary to identify the 
measurement mechanism of the constructs. This will bring a higher degree of clarity to the 
measures and explain clearly how they work. In addition, further Rasch based analyses with 
larger samples and using more recent analytical methods is desirable.  
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Chapter 5: Application of new patient-reported outcomes in 
international research 
5.1 Introduction and articles 
This chapter discusses three studies relating to the application of PROs in international 
research studies. Important considerations include the cross-cultural suitability of the 
construct being measured, the language adaptation of the questionnaire content, cross-
cultural differences in the functioning of the scale and how to interpret the scores 
generated from the PRO.  
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5.1.1 Article 1: Adapting the Asthma Life Impact Scale (ALIS) for use in 
Southern European (Italian) and Eastern European (Russian) cultures 
 
Twiss J, McKenna SP, Crawford SR, Tammaru M, Oprandi NC. Adapting the Asthma Life 
Impact Scale (ALIS) for use in Southern European (Italian) and Eastern European (Russian) 
cultures. J Med Econ. 2011;14(6):729-38. doi:10.3111/13696998.2011.615356. 
 
BACKGROUND: The Asthma Life Impact Scale (ALIS) is a disease-specific measure used to 
assess the quality-of-life of people with asthma. It was developed in the UK and US and has 
proven to be acceptable to patients, to have good psychometric  properties, and to be 
unidimensional. 
OBJECTIVE: This paper reports on the adaptation and validation of the ALIS for use in 
representative Southern European (Italian) and Eastern European (Russian)  languages. 
METHODS: The ALIS was translated for both cultures using the dual-panel process.  The 
newly translated versions were then tested with asthma patients to ensure face and 
content validity. Psychometric properties of the new language versions were assessed via a 
test?re-test postal survey conducted in both countries. 
RESULTS: Linguistic nuances were easily resolved during the translation process for both 
language adaptations. Cognitive debriefing interviews (Russia n=9, male=11.1%, age mean 
(SD)=55.4 (13.2); Italy n=15, male=66.7%, age mean (SD)=63.5 (11.2)) indicated that the 
ALIS was easy to read and acceptable to patients. Psychometric testing was conducted on 
the data (Russia n=61, age mean (SD)=40.7 (15.4); Italy n=71, male=42.6%, age mean 
(SD)=49.5 (14.1)). The results showed that the new versions of the ALIS were consistent 
(Russian and Italian Cronbach's alpha=0.92) and reproducible (Russian test-re-test=0.86; 
Italian test-re-test=0.94). The Italian adaptation showed the expected correlations with the 
NHP and the Russian adaptation showed strong correlations with the CASIS and CAFS and 
weak-to-moderate correlations with %FEV1 and %PEF. In both adaptations the ALIS was 
able to distinguish between participants based on self-reported general health, self-
reported severity, and whether or not they were hospitalized in the previous week. 
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LIMITATIONS: It is possible that some cultural or language differences still exist between 
the different language versions. Further research should be undertaken to determine 
responsiveness. Further studies designed to determine the clinical validity of the Italian 
ALIS would be valuable. 
 
The article can accessed via: 
http://www.tandfonline.com/doi/abs/10.3111/13696998.2011.615356?journalCode=ijme2
0 
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5.1.2 Article 2: International development of the patient-reported outcome 
indices for multiple sclerosis (PRIMUS) 
 
McKenna SP, Doward LC, Twiss J, Hagell P, Oprandi NC, Fisk J, Grand'Maison F, Bhan V, 
Arbizu T, Brassat D, Kohlmann T, Meads DM, Eckert BJ. International development of the 
patient-reported outcome indices for multiple sclerosis (PRIMUS). Value Health. 2010 
Dec;13(8):946-51. doi:10.1111/j.1524-4733.2010.00767.x. 
 
BACKGROUND: The Patient-Reported Indices for Multiple Sclerosis (PRIMUS) comprises a 
suite of three scales for assessing symptoms, activity limitations, and quality of life in 
multiple sclerosis (MS). It was developed in the UK and has been shown to have excellent 
psychometric properties. This study describes the adaptation of eight language versions for 
Canadian English, Canadian French, French, German, Italian, Spanish, Swedish, and US 
English. 
METHODS: The PRIMUS was translated using the dual-panel process. Cognitive debriefing 
interviews conducted with MS patients assessed face and content validity. Psychometric 
and scaling properties were assessed via a two-administration postal survey conducted in 
each country involving the PRIMUS, the Nottingham Health Profile (NHP), the 
Unidimensional Fatigue Impact Scale (U-FIS), and demographic questions. 
RESULTS: Cognitive debriefing interviews demonstrated the acceptability of the new 
language versions. Analysis of survey data showed that the new language versions of the 
three PRIMUS scales were unidimensional (as indicated by fit to the Rasch model) and that 
they had good internal consistency and reproducibility. PRIMUS scale scores correlated as 
expected with those on the NHP and the U-FIS. The scales in all countries were able to 
discriminate between groups of patients on the basis of their self-reported MS severity, 
general health, and employment status. 
CONCLUSIONS: The PRIMUS was successfully adapted into eight new languages. Most of 
the tests showed the PRIMUS to have good unidimensionality and to have good internal 
consistency, reproducibility, and construct validity. The measure is now available for use in 
clinical studies and trials involving these countries and the UK. Further work is required to 
assess the measure's responsiveness. 
 
The article can be accessed via:  http://onlinelibrary.wiley.com/doi/10.1111/j.1524-
4733.2010.00767.x/full 
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5.1.3 Article 3: Interpreting scores on multiple sclerosis-specific patient 
reported outcome measures (the PRIMUS and U-FIS)  
 
 
 
 
43 
 
 
 
 
 
 
 
44 
 
 
 
 
 
 
 
45 
 
 
 
 
 
 
 
46 
 
 
 
 
 
 
 
47 
 
 
 
 
 
 
 
48 
 
 
 
 
 
 
 
49 
 
 
 
 
 
 
50 
 
5.2 Description of studies 
The first study discussed the adaptation of the Asthma Life Impact Scale (ALIS; Meads et al, 
2010) into two new languages – Italian and Russian. The ALIS is a quality of life (QoL) scale 
specific to patients with Asthma based on the needs-based approach. It was developed 
using the same development methods discussed in Chapter 4. In this study the measure 
was translated using a careful adaption procedure into Italian and Russian and then 
assessed in a psychometric study to test the functioning of the scale. The classical test 
theory (CTT) psychometric properties of the scale were evaluated (including internal 
reliability and test-retest reliability) and the construct validity of the new measures 
assessed. The adaptation procedure was successful and the measure showed good 
psychometric properties. Internal reliability (Russian and Italian Cronbach’s alpha=0.92) 
and test-retest reliability was acceptable (Russian test–re-test=0.86; Italian test–
retest=0.94). In both adaptations the ALIS was able to distinguish between participants 
based on self-reported general health, self-reported severity of disease and whether or not 
patients were hospitalized in the previous week. 
The second study discussed the international development of the Patient-Reported 
Outcome Indices for Multiple Sclerosis (PRIMUS; Doward et al, 2009b). The original 
development was described in detail in Chapter 4 (section 4.3). This study discusses the 
adaptation of the measure into eight languages; Canadian English, Canadian French, 
French, German, Italian, Spanish, Swedish and US English. During the adaptation the 
measure was translated using a standard adaptation procedure and then evaluated in a 
psychometric study that applied both CTT and Rasch analysis. The measure was translated 
successfully and showed good fit to the Rasch model in all languages. Adequate levels of 
internal reliability (Crobnach’s alpha >0.70) and test-retest reliability (Spearman rank >0.80) 
were observed. Validity assessments showed that all language adaptations were able to 
distinguish between groups based on self-reported MS severity, general health, and 
employment status. 
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The third study described the estimation of the minimal important difference (MID) for the 
PRIMUS and unidimensional fatigue impact scale (U-FIS; Doward et al, 2009b; Meads et al, 
2009). The MID is an estimate of the minimum difference that can be considered important 
from the patients’ perspective. In studies with large samples even small differences in PRO 
scores between groups can show statistical significance (Hochster, 2008). This is because 
large samples have more statistical power. In these situations it is also important to assess 
the clinical significance of the differences between the groups. Using the MID as a guide 
assists in this process. In the study MID values were calculated for the two measures using 
a range of different methods. The MID study was successful in identifying estimates for the 
PRIMUS and U-FIS. MID estimates are between 1.2-2.3 for the PRIMUS Activity scale, 1.0-
2.2 for the QoL scale and 2.4-7.0 for the U-FIS. 
Samples of the UK versions of the PRIMUS, U-FIS and ALIS are provided in Appendices 2, 3 
and 5. Copies of the full measures can be obtained from gr@galen-research.com. 
5.3 Methodology 
Ethics approval was sought and obtained where necessary for the three studies. For the 
two adaptation studies ethics approval was not required in some of the countries included. 
Each study required the transfer of data from the countries in which the work was 
conducted back to the UK. All data was anonymised before the transfer occurred. 
It is important that the adaptation of a PRO is based on a thorough adaptation 
methodology. The language used may contain many nuances and phrases easily 
understood in the original language that may not be clear to non-native speakers. 
Consequently, it is inappropriate to produce a new language version of a questionnaire by 
simply translating the content (literal translation) as it can lead to a poor translation in the 
target language.  
The adaptation methodology used in the ALIS and PRIMUS studies followed the same 
procedures. Three stages were involved in the adaptations: 
1. Translation using dual panel methodology (Swaine-Verdier et al, 2004). 
2. Cognitive debriefing interviews. 
3. Assessment of psychometric properties. 
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The dual panel method contrasts with the more frequently applied method of forward and 
backwards translation. Although this method has become the most frequently used there is 
no scientific basis for its use compared with other methods (Swaine-Verdier et al, 2004). 
The dual panel translation method consists of conducting a professional and lay panel in 
each country. The panels each require between four and seven participants. The 
professional panel includes bilingual speakers while the lay panel includes monolingual 
speakers in the target language. Using this method the professional panel works to provide 
the initial translation in the target language. Emphasis is placed on producing conceptual 
equivalence for each item rather than a simple word for word translation. As the bilingual 
panel includes individuals of a higher educational level than the average population the 
language produced is reviewed by a lay panel more representative of the general 
population. The lay panel assesses the measure for comprehension and ‘naturalness’ of 
language. Research has shown that patients prefer adaptations based on the dual panel 
method compared with the forward-backward method (Hagell et al, 2010).        
Cognitive debriefing interviews were conducted with fifteen relevant patients in each 
language adaptation to assess the applicability, comprehensiveness and relevance of the 
translated items. Interviewees completed the questionnaire in the presence of an 
interviewer who noted any obvious difficulties or hesitation over individual items. Patients 
were then asked to comment on individual items, instructions and the response format.   
After a measure has been translated it is important to evaluate its psychometric properties 
to ensure the new adaptation works in a similar way to the original. In the ALIS adaptation 
study the functioning of the two new adaptations was assessed using CTT methods 
including internal consistency and test-retest reliability. In the PRIMUS study both CTT and 
Rasch analysis were used to assess the functioning of the adaptations. Rasch analysis 
allowed the measurement properties of the adaptations to be assessed more thoroughly. 
In addition, item location ordering was also compared across languages. 
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To estimate the MID for the PRIMUS and U-FIS two main types of analysis were conducted; 
anchor-based and distribution-based. Anchor-based approaches attempt to relate change 
scores on the PRO to change in a factor of known importance. The anchors used in the 
study included published MID values for the EQ-5D (Walters and Brazier, 2005). 
Distribution methods attempt to identify a score that may be considered important above 
the ‘statistical noise’ of the measure. The distributional methods used in the study were 
the assessment of effect size, half a standard deviation and standard error of 
measurement. The final MID values were selected after considering the results produced 
from all the analyses. 
To calculate the MID data from a twelve-month, randomized, multicenter, double-blind, 
efficacy trial were used. In total nine hundred and eleven patients were available for the 
analyses from eight countries; Canada (French and English), France, Germany, Italy, Spain, 
United Kingdom, United States and Australia.  
5.4 Evaluation 
The adaptions of the ALIS and PRIMUS were successful. The content of the measures were 
translated with few problems in each language. In addition, good psychometric properties 
were observed for all language versions in both studies. The PRIMUS adaptation showed 
how Rasch analysis can be incorporated into the language adaptation process to improve 
psychometric evaluation. The methods used in both studies go beyond the basic 
requirements for new adaptations recommended in available guidelines (Wild et al, 2005). 
In these guidelines, it is recommended that forward-backward translation methods are 
used and just five patient interviews to assess content validity.   
The adaptation of the ALIS into Russian and Italian shows the content of the measure can 
be easily adapted into two new language groups. Eight new language versions were 
developed for the PRIMUS. The success of the adaptations shows good evidence for the 
methodological approach used in the adaptations. The increase in language availability for 
the new scales means that they are available for future international clinical trials and 
research studies.  
The estimates generated in the MID study are important to help interpret change scores in 
clinical trials and research studies. In addition, the MID figures also help to determine 
sample sizes necessary for future clinical studies.  
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5.4.1 Construct definition 
The conceptual basis of the PRIMUS and U-FIS were discussed in Chapter 4. The PRIMUS 
has three scales; QoL, Activity limitations and symptoms. The U-FIS, PRIMUS Activity 
limitations and symptoms scales use the World Health Organization’s (WHO) classification 
of impairments (physiological and anatomical) and activity limitations (capacity and 
performance) (World Health Organisation, 1980; 1999) as their conceptual foundation. The 
PRIMUS QoL and ALIS are based on the needs-based approach to QoL (McKenna and 
Doward, 2004).  
It is important that the construct being measured is applicable to the target culture. 
Constructs such as symptoms are less likely to be culturally centric as there should be 
consistency in the expression of symptoms across cultures. However, QoL may be 
influenced to a greater extent by the values of a particular culture. The needs-based QoL 
approach attempts to overcome this by defining QoL based on human needs, which are 
considered to be universal. Despite this, the way in which needs are satisfied may vary 
between cultures. This means the content of some PRO items developed in one culture 
may not be fully relevant in another. This is likely to be of greatest concern when 
comparing cultures that are very different such as comparing far eastern cultures with the 
western ones.    
The ideal way to ensure the cultural relevance of a PRO is to develop it in several cultures 
at the same time. This would involve conducting all stages on development in each culture. 
It is possible for some of the items to be different in each country if different issues arise. 
As long as there is a core set of items it would be possible to co-calibrate measures in 
different languages onto the same scale using Rasch analysis (Twiss and McKenna, 2015). 
Unfortunately, the scope of this work would be very large and has rarely been attempted. 
Smaller scale studies have been conducted where item generation is performed 
simultaneously in a small number of countries (McKenna et al, 2003; Whalley et al, 2004).  
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5.4.2 Psychometric methods 
In the ALIS adaptation study psychometric analyses were conducted using CTT methods. 
These included testing the internal consistency and test-retest reliability of the measures. 
The results showed that the scale had adequate internal reliability and test-retest 
reliability. In addition, evidence of construct validity was also provided in the study. The 
results were similar to those obtained in the original development study. Despite this, CTT 
methods are limited in the information they can provide regarding measurement 
equivalence. These methods were applied due to limitations in the sample sizes. 
The Rasch model offers a more thorough way of assessing measurement equivalence. In 
the PRIMUS study overall fit, item level fit and appropriate functioning of the response 
options was observed for each language separately. This indicates that the scales all 
worked well in each language. The severity location of the individual items on the 
underlying scale was also investigated. The mildest and most severe items were found to 
be the same in each language version.  
A more thorough investigation of measurement equivalence would have been provided by 
a DIF analysis. It was not possible within the scope of the study to assess DIF by language 
version as this would have required a large level of additional work. This would involve 
analysing the dataset as a whole and attempting to identify the presence of DIF between 
languages. If DIF is identified it is necessary to assess the extent to which it influences the 
calculation of the Rasch estimates. The importance of any identified DIF can be tested using 
a method outlined by Tenant and Pallant (2007). Estimates based on a pure dataset, where 
items exhibiting DIF are removed, are compared with estimates based on the original 
dataset. Further analyses are necessary to investigate the extent and importance of DIF 
across the language versions.   
There is no gold standard method of assessing MID and so several methods are often used. 
Different distribution-based statistics are available. However, these different approaches 
usually produce different magnitudes of MID. In addition, the results often differ to those 
obtained using anchor-based estimates (Turner et al, 2010). Anchor-based methods are 
usually given more weight when estimating the MID as they relate scores to other 
meaningful measures. However, these estimates also have limitations. If a comparator 
measure is used it is important for it to be adequately related to the PRO being studied 
(Puhan et al, 2008; Schunemann et al, 2003). In addition, global change items are 
frequently used but little is known about the reliability of these assessments (Guyatt et al, 
2002; Norman et al, 1997).   
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In estimating the MID other considerations should also be made. Previous research has 
suggested that MID may be different for patients with different levels of severity (Hajiro et 
al, 2002; Guyatt et al, 2002). The PRIMUS and U-FIS study investigated the MID in a fairly 
mild sample of patients with relapsing remitting MS. The MID may need to be 
reinvestigated in different MS samples. In addition, it is possible that the MID varies 
depending on whether a patient improves or deteriorates (Cella et al, 2002; Kwok et al, 
2010; Colangelo et al, 2009). In the present study there was a bi-directional difference for 
the U-FIS with individuals who improved having a larger MID than those who deteriorated. 
This was not found for the PRIMUS scales.  
5.5 Chapter summary 
The ALIS and PRIMUS were adapted successfully into several new language versions. These 
new versions are now available for international research studies. Both adaptations used a 
unique dual panel methodology for the translation. This methodology is widely used and is 
the only one applied to adaptations of needs-based measures. The PRIMUS adaptation 
showed how Rasch analysis can be used to improve psychometric evaluation of adapted 
language versions. Adaptations for both measures would benefit from further analysis to 
assess for DIF by language.  
The MID study was successful in providing estimates for the PRIMUS and U-FIS. The 
estimates will help interpretation of scores and sample size determination for future trials. 
The MID values provided are specific to patients with relapsing remitting MS. Further 
analyses may be necessary to determine MID estimates for other forms of MS.  
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Chapter 6: Evaluation of existing patient-reported outcomes 
6.1 Introduction and articles 
Three studies are discussed that describe the evaluation of established PRO measures. The 
PROs are evaluated in relation to their construct definition and statistical methodology.     
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6.1.1 Article 1: Validation of the mood disorder questionnaire for screening 
for bipolar disorder in a UK sample 
 
Twiss J, Jones S, Anderson I. Validation of the Mood Disorder Questionnaire for screening 
for bipolar disorder in a UK sample. J Affect Disord. 2008 Sep;110(1-2):180-4. doi: 
10.1016/j.jad.2007.12.235. 
 
BACKGROUND:  The Mood Disorder Questionnaire (MDQ) was designed as a screening 
questionnaire for bipolar disorder. Previous research has raised questions about the 
suitability of the MDQ structure for screening for bipolar II disorder. This study investigated 
the optimal sensitivity and specificity cut-off thresholds for the MDQ in bipolar I and bipolar 
II patients in a UK sample. 
METHODS:  The MDQ was administered to patients before attending a tertiary mood 
disorders clinic. Diagnostic interviews were used to determine DSM-IV diagnoses and these 
were used as the gold standard against which to investigate the performance of the MDQ. 
RESULTS: 54 patients with bipolar spectrum disorder and 73 patients with unipolar 
depressive disorder completed the MDQ. With the original scoring criteria (symptoms and 
supplementary questions) the sensitivity for bipolar disorder was 0.76 (bipolar I disorder 
0.83, bipolar II disorder 0.67) with specificity 0.86. The optimal cut-off score in the current 
sample was a score of 9 or more endorsed symptoms without applying the supplementary 
questions (sensitivity of 0.90 and 0.88 for bipolar I and bipolar II groups respectively with a 
specificity of 0.90). 
LIMITATIONS: The sample was drawn from a tertiary mood disorders clinic. 
CONCLUSIONS: The MDQ appears to be a useful screening tool for bipolar spectrum 
disorder in UK psychiatric practice with sensitivity for bipolar II disorder improved by 
dropping the supplementary sections. Further investigation of the optimal cut-off scores of 
the MDQ is needed to determine its utility in non-specialist and community based samples. 
 
The article can be accessed via: http://www.jad-journal.com/article/S0165-0327(08)00016-
5/abstract 
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6.1.2 Article 2: Can we rely on the dermatology life quality index as a 
measure of the impact of psoriasis or atopic dermatitis? 
 
Twiss J, Meads DM, Preston EP, Crawford SR, McKenna SP. Can we rely on the Dermatology 
Life Quality Index as a measure of the impact of psoriasis or atopic  dermatitis? J Invest 
Dermatol. 2012 Jan;132(1):76-84. doi: 10.1038/jid.2011.238. 
 
The Dermatology Life Quality Index (DLQI) is a widely used health-related quality of life 
measure. However, little research has been conducted on its dimensionality. The objectives 
of the current study were to apply Rasch analysis to DLQI data to determine whether the 
scale is unidimensional, to assess its measurement properties, test the response format, 
and determine whether the measure exhibits differential item functioning (DIF) by disease 
(atopic dermatitis versus psoriasis), gender, or age group. The results show that there were 
several problems with the scale, including misfitting items, DIF by disease, age, and gender, 
disordered response thresholds, and inadequate measurement of patients with mild illness. 
As the DLQI did not benefit from the application of Rasch analysis in its development, it is 
argued that a new measure of disability related to dermatological disease is required. Such 
a measure should use a coherent measurement model and ensure that items are relevant 
to all potential respondents. The current use of the DLQI as a guide to treatment selection 
is of concern, given its inadequate measurement properties. 
 
The article can be accessed via: 
http://www.nature.com/jid/journal/v132/n1/full/jid2011238a.html 
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6.1.3 Article 3: Psychometric performance of the CAMPHOR and SF-36 in 
pulmonary hypertension 
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6.2 Description of studies 
The first article describes a validation study in a UK sample of the Mood Disorder 
Questionnaire (MDQ; Hirschfeld et al, 2000).  The measure was developed to aid the 
diagnosis of bipolar spectrum disorders and is based closely on the DSM-IV criteria 
(American Psychiatric Association, 2000). It has three sections; symptom endorsement 
(Section 1), symptom clustering (Section 2) and severity of problems caused (Section 3). In 
Section 1 there are thirteen dichotomous items that ask patients whether they have ever 
experienced different hypomanic symptoms (e.g. “you had much more energy than usual”). 
Section 2 asks if the symptoms have ever occurred at the same time. Section 3 asks 
patients about the severity of the symptoms on a four point scale. The original validation 
study reported that the MDQ performed relatively well against DSM-IV diagnosis 
(sensitivity 0.73, specificity 0.90) in a psychiatric outpatient population (Hirschfeld et al, 
2000). The purpose of this study was to re-assess the functioning of the measure in a UK 
sample. The results showed that the measure worked well. The optimal cut-off score in the 
sample was nine or more endorsed symptoms without applying the supplementary 
questions (sensitivity of 0.90 and 0.88 for bipolar I and bipolar II groups respectively with a 
specificity of 0.90). 
 
The second article describes the evaluation of the Dermatology Life Quality Index (DLQI) 
(Finlay and Khan, 1994). This measure is the most frequently used dermatology-specific 
outcome measure and is used to determine whether patients are eligible to receive 
biological interventions for psoriasis in the UK (Smith et al, 2005, 2009; NICE, 2008a, 2008b, 
2009). It contains ten items covering symptoms, treatment, activity limitations and 
emotional reactions to having a skin disease. The classical psychometric properties of the 
questionnaire have been shown to be adequate (Basra et al, 2008). However, more recent 
analysis using Rasch analysis highlighted several weaknesses with the scale (Nijsten et al, 
2006, 2007). The aims of the study were to reassess its measurement properties using 
Rasch analysis and to determine whether the scale worked in the same way with psoriasis 
and atopic dermatitis patients. The findings showed that the measure exhibited item misfit, 
response option dysfunction and differential item functioning (DIF) by disease (psoriasis vs 
atopic dermatitis). The DIF suggested that some items are interpreted and valued 
differently in different diseases indicating that scores should not be combined for these 
two patients groups.   
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The third study compared the psychometric properties of the SF-36 (Ware et al, 2000) and 
the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR; McKenna et al, 
2006). These two measures are the most frequently used PROs for patients with pulmonary 
hypertension. The SF-36 is a generic health status questionnaire consisting of eight 
domains; physical functioning (ten items), social functioning (two items), role limitations 
due to physical problems (four items), role limitations due to emotional problems (three 
items), mental health (five items), energy/vitality (four items), pain (two items), general 
health perception (five items) and a single health transition item. The CAMPHOR is a 
pulmonary hypertension ( PH) specific measure and comprises three scales assessing 
impairments (symptoms), activity limitations (functioning) and needs-based quality of life 
(QoL; McKenna and Doward, 2004). The aim of the study was to compare the psychometric 
properties of the two scales using classical test theory (CTT) analyses. The results showed 
high ceiling effects (% scoring maximum) for the SF-36 bodily pain, social functioning and 
role emotional domains indicating a lack of item coverage or lack of suitability of the scales. 
Test-retest reliability was poor for six of the eight SF-36 domains (Spearman Rank 
correlation coefficients <0.85), indicating high levels of random measurement error. Three 
of the SF-36 domains did not distinguish between WHO classes. In contrast, all CAMPHOR 
scales exhibited good distributional properties, test-retest reliability and distinguished 
between WHO functional classes.  
6.3 Methodology 
Ethics approval was gained for the collection of data in each of the three studies. The 
studies involved secondary analysis of anonymised data.    
In the MDQ study the aim was to assess how well the instrument could correctly identify 
patients with bipolar disorder. The sample included one hundred and twenty seven 
patients, fifty four with a bipolar spectrum disorder and seventy three with a unipolar 
diagnosis. Participants were sequential outpatient attendees of a tertiary NHS Specialist 
Service for Affective Disorders who completed the MDQ and then received a semi-
structured clinical interview covering current and past mood disorder (DSM-IV-TR 
diagnosis; American Psychiatric Association, 2000). The MDQ was evaluated using classical 
psychometric methods and by ROC curve analysis.  Internal reliability was assessed using 
Cronbach’s alpha (Cronbach, 1951). ROC curve analysis was used to assess the measure’s 
sensitivity (proportion of patients with the disease correctly identified) and specificity 
(proportion of patients without the disease correctly identified). Full diagnostic interview 
using DSM-IV criteria was used as the gold standard for identifying patient’s disease type.  
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In the DLQI study, one hundred and forty seven patients with psoriasis and one hundred 
and forty seven patients with atopic dermatitis were included. The evaluation used Rasch 
analysis to assess the measurement properties of the scale. The analyses conducted were 
consistent with published guidelines (Tennant and Conaghan, 2007). Several fit indices 
were assessed including overall fit to the model, individual item fit, response option 
functioning, coverage of the trait by the items and differential item functioning by disease. 
The study comparing the SF-36 and CAMPHOR included data collected in Australia and New 
Zealand (Ganderton et al, 2011). Sixty five participants completed the SF-36 and CAMPHOR 
at two time-points, two weeks apart. They also provided demographic and disease 
information (age, gender, WHO class and PH type). Participants completed the SF-36 
immediately followed by the CAMPHOR at each time point. CTT analyses included 
distributional properties (including % scoring the minimum and maximum), internal 
consistency (Cronbach’s alpha), test-retest reliability and known group validity by WHO 
functional class.      
6.4 Evaluation 
The MDQ study represented the first assessment of the functioning of the screening tool in 
a UK sample.  The sensitivity and specificity values were similar to those in the previous 
research studies in other non-UK samples (Isometsa et al, 2003; Kemp et al, 2008; Miller et 
al, 2004; Weber Rouget et al, 2005; Benazzi and Akiskal, 2003). The article makes an 
important contribution to the detection of Bipolar Disorder in the UK.   
Given the prominence of the DLQI it is important to have a thorough evaluation of the 
functioning of the measure. Previous researchers had highlighted some of the deficiencies 
in the scale (Nijsten et al, 2006, 2007). This study supported these findings and showed the 
measure worked differently in different disease areas. Importantly, the research suggests 
that the widespread use of the measure, particularly its use for guiding treatment decisions 
should be questioned.  
The comparison of the SF-36 and CAMPHOR provides a clear illustration of the functioning 
of each of the measures for patients with pulmonary hypertension. As these are the two 
most widely used measures in the disease area the study helps researchers identify the 
most appropriate scale to use.   
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6.4.1 Construct definition 
The MDQ was developed from clinical experts rather than patients. Although no formal 
conceptual model is specified for the measure, it is based closely on the diagnostic and 
statistical manual of mental disorders (DSM-IV) criteria for Bipolar Disorder. The DSM-IV 
lists several different types of Bipolar Disorder including Bipolar I and Bipolar II disorder. 
Bipolar I disorder is characterised by manic episodes in which patients experience 
increased arousal and energy levels which may or may not be accompanied by episodes of 
depression. Bipolar II disorder is characterised by episodes of depression and hypomania, a 
lesser form of mania. A structured clinical interview for DSM-IV Axis I Disorders (SCID-I) is 
used for making the diagnoses (First et al, 1996). The criterion requires that patients have 
experienced a number of manic/hypomanic symptoms together and that the mood issues 
cause significant distress or impairment of social, occupational or other areas of 
functioning.   
The approach to mental health adopted by the DSM-IV has been criticized for a variety of 
reasons. It has been argued that there is commonly overlap between different disorders 
and that distinguishing between conditions such as mania and schizophrenia is challenging 
(Bentall, 2003). According to this view the strict definitions suggested in the DSM-IV may 
not reflect the fluidity of mental health issues. Such arguments undermine the validity of 
some parts of the classification system. In addition, it has been argued that the use of the 
DSM-IV is leading to the over medicalisation of the general population. For example, the 
most recent version of the DSM (DSM-V; American Psychiatric Association, 2013) has 
lowered the threshold for the diagnosis of depression and generalised anxiety disorder. 
Finally, the content of the DSM-IV was developed via a ‘task force’ of clinical experts using 
closed practices which is likely to cause bias (Cosgrove and Regier, 2009). Despite these 
criticisms the DSM-IV provides a clearly operationalised system for categorising mental 
health conditions. By adhering closely to the DSM-IV approach the MDQ benefits from the 
large body of work conducted in this area.     
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No formal conceptual basis for the DLQI is provided by the authors. The content of the 
measure was derived from information provided by one hundred and twenty dermatology 
outpatients. Patients were asked to write down all the ways that their skin condition 
affected them. The content of the measure was then based on the most frequently 
mentioned issues. The interpretation of the results and selection of items was not guided 
by a theoretical underpinning. Failure to describe the conceptual basis of an outcome 
measure adequately is not acceptable as it means that the validity of the scale must be 
questioned. It is not surprising that without a clear conceptual basis the DLQI includes a 
mixture of types of outcomes including symptoms (e.g. Itchy, sore, painful, or stinging), 
functioning (e.g. Interferes with shopping/looking after home/garden) and other issues 
such as treatment problems.  
The SF-36 has gone through numerous stages of evolution which makes tracking the 
original conceptual basis challenging. Items used in the SF-36 scales were derived from 
several different instruments that had been in use for twenty-to-forty years (Ware et al, 
1992). A shorter twenty-item SF-36 questionnaire was created first from the larger previous 
scales (Stewart et al, 1988). It was then decided to lengthen the scale to include thirty six 
items. The reason for lengthening the measure was an attempt to increase its sensitivity.  
The underlying theoretical basis of the measure is not clear and the reason for selecting the 
particular domains is not explicitly stated. Confusingly different conceptual frameworks for 
the measure have been suggested in which the domains are combined into different higher 
order scales such as psychical functioning, general and mental functioning  (Keller et al, 
1998). As discussed in Chapter 2 (section 2.5.3), conceptual frameworks are limited in their 
explanation of a construct if they are not embedded in a wider theoretical body of work.  
The weaknesses in both these measures have important clinical implications. In clinical 
practice, it is not clear how clinicians or practitioners should interpret scores on the 
measures making their use very limited. In addition, as it is not clear what each PRO 
measures, results may be misinterpreted in clinical trials. 
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In contrast the CAMPHOR scales were based on clearly defined conceptual foundations. 
The impairments (symptoms) and activity limitations (functioning) scales are based on the 
World Health Organization’s (WHO) classification of impairments (physiological and 
anatomical) and activity limitations (capacity and performance) (World Health 
Organisation, 1980, 1999). The QoL scale utilizes the needs-based approach to quality of 
life (McKenna and Doward, 2004). Despite this, the construct definition for the three 
CAMPHOR scales could be improved by defining their underlying measurement 
mechanisms (Stenner et al, 2013). Further work is necessary to identify clearly how each of 
the measures work and what governs the location of the items on the underlying construct.  
6.4.2 Psychometric methods 
ROC curve analysis was used to assess the most appropriate cut-off values for the MDQ. 
The results showed that the scale had greater levels of sensitivity and specificity if only the 
first section covering symptom reporting was used. A cut off value of nine provided the 
greatest level of sensitivity and specificity. This contrasts with the original study which used 
the second and third qualifying questions and identified a cut off score of seven. The ROC 
curve analyses were appropriate for the assessment and allowed thorough investigation of 
the performance of the screening tool. 
Cronbach’s alpha coefficients were also calculated for the symptoms section and found to 
be adequate (Alpha coefficient = 0.91; Item–item total correlations ranged from 0.41–
0.81). Unfortunately, Cronbach’s alpha is limited in its ability to inform on the 
measurement properties of a scale and the alpha value can be artificially increased by 
including similar items (Streiner, 2003). Assessment using Rasch analysis would have 
provided greater detail on the measurement properties of the scale and allowed the 
assessment of unidimensionality, item fit and coverage of the underlying trait. 
Unidimensionality was not assessed in the original development of the DLQI (Finlay and 
Khan, 1994). Subsequently the measurement properties have been assessed using a two-
parameter form of IRT and suggested that fit was adequate (Mazzotti et al, 2006). 
Unfortunately, this analysis was lacking in detail and firm conclusions cannot be drawn 
from the data presented. Furthermore the Rasch model is a more powerful IRT model as it 
provides measurement that has specific objectivity and sufficiency (Stenner, 1994; Linacre, 
1992). These are key requirements of fundamental measurement and allow interval level 
measurement to be achieved.      
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The DLQI showed overall misfit, item level misfit, response option dysfunction, poor 
measurement range and DIF by disease. The combination of these results raises concerns 
about the suitability of the DLQI for guiding treatment decisions as is the case in the UK. 
The DLQI has been described as a first generation health related quality of life (HRQL) 
measure (Nijsten et al, 2007) as it was developed without the use of modern psychometric 
methods and without a clear conceptual foundation.      
Classical psychometric analyses were used to compare the functioning of the CAMPHOR 
and SF-36 due to the sample limitations caused by the rarity of the disease. It would have 
been desirable to assess the functioning of the measures using Rasch analysis. The 
CAMPHOR was developed using Rasch analysis and each of its scales were found to fit to 
the model (McKenna et al, 2006). The SF-36 was not developed using Rasch analysis and 
the scaling properties of the measure are unclear. Many of the scales are too short for 
proper assessment of these properties. For example, the bodily pain and social functioning 
scales contain only two items. The physical functioning scale contains ten items and the 
measurement properties of the scale have been investigated in several studies. The results 
of these studies have been mixed. Two papers have indicated misfit to the Rasch model 
(Haley et al, 1994; McHorney et al, 1997). Other studies have suggested that the physical 
functioning scale shows better fit (Taylor and McPherson, 2007). Evidence of DIF by disease 
has also been identified in other studies suggesting that scores may not be comparable in 
different diseases (Dallmeijer et al, 2007).  
6.5 Chapter summary 
In this chapter three studies evaluating the psychometric properties of existing scales have 
been considered. Each study makes an important contribution to knowledge in their 
respective fields. The screening tool for Bipolar disorder has provided an effective way for 
the disease to be screened in everyday practice in the UK. The evaluation of the DLQI 
exposed limitations of the measure. The results suggest that the DLQI may not be suitable 
for making treatment decisions. Finally, the comparison of the two most widely used PROs 
in pulmonary hypertension showed the relative strengths of each scale which is essential 
information for researchers and clinicians selecting the most useful outcome measure.  
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Each study was evaluated using the criteria discussed in Chapters 2 and 3. Weaknesses in 
the development methods of the scales were evident. In particular, the SF-36 and DLQI 
have poorly defined constructs and weak measurement properties. These measures can be 
considered first generation outcomes and new outcomes adopting modern psychometric 
standards are necessary in order to improve the validity and quality of measurement in 
these areas.    
 
 
76 
 
Chapter 7: Co-calibrating disease-specific patient reported outcomes 
7.1 Introduction and article 
In this chapter one article is discussed that shows an innovative method for placing two 
different disease-specific PROs onto the same scale so that scores can be combined and 
compared across diseases. The process uses Rasch analysis (Rasch, 1960/1980) to co-
calibrate the scales onto the same measurement continuum. Two dermatology-specific 
outcome measures are co-calibrated in the study; the Psoriasis Quality of Life Scale 
(PSORIQoL; McKenna et al, 2003) and the Quality of Life in Atopic Dermatitis Scale (QoLIAD; 
Whalley et al, 2004). The method used will be described and its benefits discussed. The 
importance of the conceptual basis and psychometric properties of the scales are also 
discussed.   
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7.1.1 Comparing the impact of psoriasis and atopic dermatitis on quality of 
life: co-calibration of the PSORIQoL and QoLIAD 
 
Twiss J, McKenna SP. Comparing the impact of psoriasis and atopic dermatitis on quality of 
life: co-calibration of the PSORIQoL and QoLIAD. Qual Life Res. 2015 Jan;24(1):105-13. doi: 
10.1007/s11136-014-0630-y. 
 
BACKGROUND: Disease-specific patient-reported outcome (PRO) measures are designed to 
be highly relevant to one disease. It is widely believed that comparisons of outcomes 
between patients with different diseases are only possible using generic measures. The 
present study employs a novel method of using Rasch analysis to co-calibrate scores from 
different disease-specific PRO measures, allowing scores to be compared across diseases. 
METHODS: Psoriasis patients (n = 146, mean age = 44.4, males = 50 %) completed the 
Psoriasis Quality of Life scale (PSORIQoL) and atopic dermatitis patients (n = 146, mean age 
= 45.5, males = 50 %) the Quality of Life in Atopic Dermatitis scale (QoLIAD). Both measures 
employ the needs-based model of QoL, and they share five common items-providing a link 
between assessments. The groups were analysed  separately, and then combined to test fit 
to the Rasch model.  
RESULTS: Both scales showed good fit to the Rasch model after minor adjustments 
(PSORIQoL: χ (2) p = 0.25; QoLIAD: χ (2) p = 0.51). For the combined dataset, one common 
item showing differential item functioning by disease was removed and fit to the Rasch 
model was achieved (χ (2) p = 0.08). The co-calibrated scale successfully distinguished 
between perceived severity groups (p < 0.001). 
CONCLUSIONS: It is possible to co-calibrate scores on the PSORIQoL and QoLIAD. This is one 
of the first studies in health research to demonstrate how Rasch analysis can be used to 
make comparisons across diseases using different disease-specific measures. Such an 
approach maintains the greater relevance and, consequently, accuracy associated with 
disease-specific measurement. 
 
The article can be accessed via: http://link.springer.com/article/10.1007%2Fs11136-014-
0630-y 
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7.2 Description 
In dermatological research individuals with different skin conditions are often combined 
(Potocka et al, 2008, 2009; Ludwig et al, 2009; Quandt et al, 2008; Papoutsaki et al, 2007; 
Schmitt et al, 2007). When this is done generic PROs are often used, as their content is not 
specific to one condition. However, as discussed in Chapter 6, generic outcomes often lack 
the sensitivity of disease-specific measures (Twiss, 2013; Shikiar et al, 2006; Angst et al, 
2008; Dawson et al, 2012). In addition, older generic outcomes often have poor 
psychometric properties (Twiss, 2012). An alternative method of assessing outcomes for 
patients with different diseases was discussed in the article. The method used Rasch 
analysis to co-calibrate different disease-specific measures onto the same measurement 
scale. 
This method has been used frequently in educational settings to equate tests of different 
difficulty levels and to standardise tests results from one year to another (Wright, 1993). 
For example, students of different ability levels may sit different forms of a maths test. In 
order to provide grades to the students the different forms of the maths tests must be 
placed onto the same measurement scale. Using this approach it is possible for patients 
with different diseases to be compared when they have completed different disease-
specific patient reported outcomes (PROs). 
There are two commonly used approaches to co-calibrating different outcome measures 
(Vale, 1986). These are: 
1. Common person design. In this method participants complete both forms of the test 
and then the measures are co-calibrated. The tests do not have overlapping item 
content but must measure the same construct.  
2. Common Item design. Here participants complete only one form of a test but the 
two tests have item content that is common to both measures.  Again, it is essential 
that the different tests measure the same construct.  
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Previous research has co-calibrated different disease-specific PROs using a common person 
design (Latimer et al, 2012; Thissen et al, 2011; Crane et al, 2008). A clear limitation of this 
method is that patients must complete both PROs. This may require patients to complete a 
disease-specific PRO that is not relevant to their disease. Alternatively a common item 
design can be used. In order to conduct a common item co-calibration it is necessary for 
different PROs to have the same conceptual foundation and have overlapping item 
content. Outcome measures based on the needs-based approach to quality of life (QoL) 
fulfil these requirements. 
The PSORIQoL is a psoriasis-specific measure of QoL and the QoLIAD is an atopic dermatitis-
specific measure of QoL. Both diseases affect the skin but differ based on factors such as 
areas affected, itchiness, age of onset, triggers, and associated disorders (O'Neill et al, 
2011; Bowcock and Cookson, 2004). Each measure was developed based on the needs-
based model of QoL (McKenna and Doward, 2004). Due to this the PSORIQoL and QoLIAD 
share a number of common items.  
The results of the Rasch analyses showed that it was possible to co-calibrate the two scales. 
The co-calibrated scale showed good measurement properties across a range of analyses. 
In addition, the scale was able to distinguish between severity groups providing further 
evidence of validity.    
Samples of the PSORIQoL and QoLIAD are provided in appendices 7 and 8. Copies of the full 
measures can be obtained from gr@galen-research.com. 
7.3 Methodology 
Secondary analyses were conducted on available data. Ethics approval was sought and 
obtained in the original studies. Informed consent was gained from the patients and all 
data anonymised. 
The sample consisted of two hundred and ninety two participants from the UK (one 
hundred and forty seven with psoriasis and one hundred and forty seven with atopic 
dermatitis). Psoriasis patients completed the PSORIQoL and atopic dermatitis patients 
completed the QoLIAD. Both scales were developed using the Rasch model and contain five 
common items. The responses to the common items were used as anchors for the co-
calibration analysis.  
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Three stages were involved in the co-calibration: 
1. The PSORIQoL and QoLIAD were analysed separately to test fit to the Rasch model. This 
was used to establish whether the measurement properties of the scales were suitable for 
co-calibration. 
2. Data from both PROs were then combined using a common item design.  Rasch analysis 
fit statistics for the common items and overall scale were investigated. 
3. The validity of the method was then investigated by relating the co-calibrated scores to 
disease type and perceived disease severity. 
7.4 Evaluation 
This is one of the first studies to apply Rasch analysis to co-calibrate two disease-specific 
PROs using a common item design. The study has clear advantages over approaches that 
use generic outcomes. As the measures are specific to each disease they are more relevant 
to patients in each group. This should ensure that the outcomes are more sensitive to 
change than generic measures (Twiss, 2013; Shikiar et al, 2006; Angst et al, 2008; Dawson 
et al, 2012). Generic measures frequently used in dermatology have weak measurement 
properties (Nijsten et al, 2006; 2007; Twiss et al, 2012). In addition, when generic outcomes 
are used in different diseases differential item functioning (DIF) by disease is also a problem 
(Dallmeijer et al, 2007; Taylor and McPherson, 2007; Jenkinson et al, 2001). This research 
shows that items are valued differently in different diseases so that scores may not be 
comparable. 
Practically, co-calibration has a clear application in research studies combining patients 
with different diseases that currently use generic PROs. In addition, this method may also 
be useful in comparative effectiveness studies that are used to make decisions about the 
allocation of scarce health resources (Chalkidou and Anderson, 2009). The relative 
effectiveness of treatment interventions in different conditions can be compared in these 
situations using a common QoL metric. However, further research is needed to compare 
the effectiveness of this method with standard generic PROs and to test the usefulness of 
the method in comparative effectiveness studies.  
As a large number of disease-specific outcomes have been developed based on the needs-
based approach there is potential to co-calibrate scales across a number of different 
disease areas.   
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7.4.1 Construct definition 
In order to co-calibrate disease-specific outcomes using a common item design it is 
essential that the scales measure the same construct. In the present study the needs-based 
approach was used. This has been applied in a large number of different diseases and is the 
most widely applied approach in QoL research (McKenna and Doward, 2004). The approach 
has been described in more detail in Chapters 2, 4 and 5. Although each disease impacts on 
patients’ ability to meet their needs in different ways there is commonly overlap as needs 
are universal. For example, satisfaction of social needs may be restricted in a range of 
conditions including rheumatoid arthritis, multiple sclerosis and Crohn’s disease. The 
strength of this approach is that it can be applied across a wide range of different 
conditions.  
Although several outcomes have been developed based on the needs-based approach few 
other outcomes have been developed using a common conceptual foundation. The clinical 
application of the co-calibration method is currently limited for this reason.  
7.4.2 Psychometric methods 
Rasch analysis was used to co-calibrate the two scales. The process of co-calibration is 
possible due to the ability of the Rasch model to handle missing data. Ability/item 
parameters can still be estimated with missing responses present. This means two scales 
can be calibrated onto the same scale where only a proportion of the items have been 
completed by both samples.  
One of the limiting factors in this approach is that many scales do not fit the Rach model. 
Substantial manipulations, such as item removal and restructuring the response format, 
may be necessary in order make the scales fit. In many cases even after these 
manipulations fit to the model may be unsatisfactory. Ultimately, lack of fit to the Rasch 
model will preclude the application of this method for many PROs.  
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In the present study five items were available initially for the co-calibration. One of the 
items exhibited DIF by disease and had to be deleted leaving four items as anchors. There is 
no consensus in the literature on how many common items are needed for co-calibration. 
However, the general view is that the more items available the more robust the item 
calibrations will be (Vale, 1986; Wolfe, 2000). Research has also shown that successful co-
calibration can be achieved with relatively few items if the common and unique items are 
of good enough quality to ensure good estimates of ability (Wingersky and Lord, 1984). In 
future needs-based instrument development additional emphasis will be placed on 
selecting items that overlap with existing scales.     
7.5 Chapter summary 
This study included in this chapter showed that it was possible to co-calibrate two different 
disease-specific PROs using Rasch analysis. Both PROs were based on the same conceptual 
foundation: the needs-based approach to QoL. As both measures have overlapping item 
content a common item design was used. This method is likely to be most applicable in 
research studies which combine patients with different diseases where generic outcomes 
are usually used. In addition, the approach may be suitable for comparative effectiveness 
studies. A large number of PROs are available based on the needs-based approach to QoL 
making co-calibration across several different diseases possible. 
Limitations in the method were identified. These relate to the need for different PROs to 
have the same conceptual foundation and the requirement that the scales fit the Rasch 
model. Few available scales are based on a strong theoretical foundation and also fit the 
Rasch model. These limitations could be overcome if a wider approach to PRO 
measurement is adopted where disease-specific PRO measures in different disease areas 
are developed based on the same conceptual foundation.  
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Chapter 8 – Summary and conclusions 
8.1 Overview 
The thesis has presented 10 research studies concerned with the improvement of PRO 
measurement. The research has covered a wide range of topics:  
- The development of new PROs  
- Application of PROs in international research 
- The evaluation of existing PROS 
- Co-calibration of disease-specific PROs  
 
An underlying aim of all the research was to improve the standards of measurement in PRO 
research. Two common themes run through the work: 
- The importance of clear PRO construct definition 
- High quality psychometric measurement methods 
 
This chapter examines the contribution of the research, reviews the themes, highlights 
areas for future research and considers whether the aims of the research have been met.  
8.2 Contribution of the research 
Chapter 4 described the development of 3 new disease-specific PROs. Each of the measures 
makes a valuable contribution to outcome measurement within their relevant disease area. 
All of the measures were based on a clear construct definition and applied Rasch analysis in 
their development. Consequently, the measures achieve a high quality of measurement. 
The scales are valuable in clinical trials and for monitoring patients’ progress in clinical 
practice.  
Chapter 5 described the adaptation of two measures into a number of additional languages 
using a unique dual panel approach. One of the studies exhibited a method of cross-
cultural validation that included Rasch analysis. The development of the adaptations allows 
the measures to be used in international clinical trials and research studies increasing their 
practical value.  
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Chapter 5 also discussed the estimation of the minimal important difference (MID) for the 
Patient-Reported Indices for Multiple Sclerosis (PRIMUS; Doward et al, 2009b) and the 
Unidimensional Fatigue Impact Scale (U-FIS; Meads et al, 2009). This study was successful 
in providing estimates. These will help interpretation of scores to determine whether or 
not an intervention is effective and for sample size determination.   
In Chapter 6, three widely used PROs were evaluated based on the criteria specified in 
Chapters 2 and 3. The Dermatology Life Quality Index (DLQI) (Finlay and Khan, 1994) and 
the SF-36 (Ware et al, 2000) were found to have several limitations. The findings have 
important implications for the way in which the measures are used. Several scales of the 
SF-36 were shown to be unsuitable in pulmonary hypertension due to high ceiling effects, 
poor reliability and poor construct validity. The Cambridge Pulmonary Hypertension 
Outcome Review (CAMPHOR; McKenna et al, 2006) provided more sensitive measurement 
with less measurement error. The DLQI also showed weaknesses including misfit to the 
Rasch model, response option dysfunction and differential item functioning (DIF) by 
disease. The weak psychometric properties of the DLQI are concerning as the measure is 
currently used to guide treatment decisions in the UK. The results of this study suggest that 
using the measure in this way may lead to poor clinical decision making.   
In Chapter 7, a new method for co-calibrating scores from two disease-specific PROs was 
discussed. This method offers a way of combining PRO data from patients with different 
diseases that complete different disease-specific measures. Ordinarily, generic outcomes 
would be used for this purpose. As discussed in Chapter 6, generic outcomes often lack the 
sensitivity of disease-specific measures and the older generic measures suffer from poor 
measurement properties (Twiss, 2013; Nijsten et al, 2006; 2007; Dallmeijer et al, 2007; 
Taylor and McPherson, 2007; Jenkinson et al, 2001). This method has the potential to 
provide more accurate and sensitive data when combining patients with different diseases.   
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8.3 Themes of the thesis 
8.3.1 Clear construct definition 
Clear construct definition provides the cornerstone of a measure and gives its rationale. 
Although it is fundamental to good, purposeful measurement it is often not considered 
adequately by the developers of PROs (Gimeno-Santos et al, 2011; McKenna, 2011a). This 
part of the measure development is perhaps the most challenging. It requires a thorough 
understanding of different types of health outcome constructs and which is required for 
the specific study. It also demands a detailed justification and explanation for the 
construct. There is no simple way of assessing whether a measure has captured the 
intended construct adequately (Cano and Hobart, 2011). Evidence must be sought through 
several approaches including face, internal, content and construct validity assessments.  
In Chapter 2 three different approaches to construct definition were discussed. These 
included clearly defining the theoretical foundation of the construct, providing a 
conceptual framework for the outcome measure and producing a measurement 
mechanism for the construct.    
The approach to construct definition in each of the PROs included in the thesis has been 
evaluated. Evaluation of the DLQI and SF-36 showed limitations in the definition of the 
constructs measured by each. The DLQI includes different types of outcome and does not 
have a clear theoretical foundation. The SF-36 was developed based on previous outcome 
measures rather than being based on a clear underlying theory. A conceptual framework 
for the SF-36 has been provided that shows the items group into different domains. 
However, the content of the SF-36 is combined into different kinds of outcome depending 
on which scoring method is applied. Furthermore, there is little justification for the 
domains selected due to the lack of theoretical underpinning. Due to these limitations it is 
not clear exactly what each intends to measure. Unfortunately, this is frequently found in 
older PROs as the conceptual foundation of the measures was not considered adequately 
(Gimeno-Santos et al, 2011). 
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There are serious consequences related to not clearly defining the underlying construct of a 
PRO. In clinical practice it is vital that each outcome measure used should have a clear 
clinical purpose. This helps clinicians and practitioners to monitor properly the patient’s 
condition. If a PRO is not developed based on a clear theoretical foundation then it will not 
help clinicians and practitioners to understand the patient’s experience and/or could 
mislead them into making the wrong decisions for the patients care. In addition, the use of 
such measures in clinical trials can also provide misleading findings. Due to this, patients 
may not receive appropriate interventions for their condition.          
In contrast, needs-based QoL measures provide a clearer theoretical basis for the construct 
they assess. They define QoL in relation to the satisfaction of human needs and are 
supported by a large body of research on human motivation (Maslow 1970; Max-Neef et al 
1991; Kenrick et al 2010). The development methodology clearly identified needs affected 
by each condition and this guided item selection. 
Despite this, further explanation of this construct is necessary in order to provide a 
measurement mechanism. Attempts are needed to explain how specific components can 
be manipulated to allow items to represent different levels of the construct (Stenner et al, 
2013). This will lead to greater quality in measurement.   
    
8.3.2 Psychometric measurement approach     
Preference has been given in this thesis for the application of Rasch analysis (Rasch, 
1960/1980) for developing and evaluating PROs. The main strength of the Rasch model is 
its embodiment of fundamental measurement. When data fit the Rasch model they 
achieve interval level measurement. Other forms of IRT do not provide fundamental 
measurement so were not considered in the research. 
However, Rasch analysis is not without its detractors and the model tends to divide IRT 
researchers into those for and against. Its detractors consider the model to be overly 
restrictive and not reflective of data produced by most PROs (Ghaemi, 2011). The model is 
considered overly restrictive as it provides only one parameter; a difficulty parameter. This 
means that all items share the same level of discrimination. However, it is this restriction in 
the model that allows fundamental measurement to be achieved. When an additional 
discrimination parameter is added as with the two and three parameter IRT models, the 
chance of interval measurement is lost as measurement invariance cannot be achieved.  
87 
 
The difference between the approaches taken using the Rasch model and those using two 
and three parameter models are subtle but important. One important difference is due to 
general IRT approaches attempting to fit a model to the data whereas the Rasch approach 
fits data to the pre-defined model (Andrich, 2004). In a two-parameter model each item is 
allowed to have a different level of discrimination so a model that best describes the data is 
selected. In contrast, the Rasch model is defined a priori so data are tested for adequacy 
given model requirements. Justification of poor measures using IRT models that do not 
provide fundamental measurement is an unsatisfying methodological approach (Andrich, 
2004).   
8.4 Limitations of the thesis 
8.4.1 Areas not covered 
It has not been possible to discuss all of the important aspects of PRO measurement within 
the confines of this thesis. One important component of PRO development not discussed in 
detail is PRO design. This area includes the design of the instructions, time reference for 
the items, item design and format of the response options. Much research has been 
conducted into each of these components (Tanur 1992; Stull et al 2009; Schneider et al, 
2013; Streiner and Norman, 1989; Khadka et al, 2012). This is an area of great importance 
as it forms a means by which the conceptual basis of the measure is realised and data is 
collected for the psychometric analyses. Due to this the design aspects of the new PROs 
included in this thesis were considered carefully.    
8.4.2 Methodological limitations 
Any research study is guided by the knowledge and practices of the time. In health 
outcomes research large changes have occurred over the last two decades. Until recently 
classical test theory was the dominant force in the area. This has been challenged by the 
emergence of IRT and Rasch analysis (Belvedere and Morton, 2010). These new methods 
have brought new knowledge and a gradual improvement in the quality of measurement in 
the field. This gradual progression and improvement is part of the scientific process and the 
research presented in this thesis is subject to the same gradual shifts.   
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Knowledge of the practical application of Rasch analysis is advancing as more research is 
conducted. The statistical analyses conducted as part of the Rasch analyses in this research 
have been superseded by slightly different techniques. For example, methods for detecting 
multidimensionality have changed over time. A method that involves comparing estimates 
from two subsets of items loading most differently on the first residual components 
analysis is often now used for this purpose (Smith, 2002). This method was not used in the 
development of some of the earlier needs-based PROs. In addition, new ways of identifying 
local dependence in the Rasch model are also now used (see Chapter 4, section 4.4.2). Both 
of these developments may have influenced item selection in some of the needs-based 
PROs. 
8.5 Future research 
New measures are being developed based on the needs-based approach to QoL. This 
includes new measures for Crohn’s disease, intestinal failure, ulcerative colitis and 
neurofibromatosis. These developments will help improve measurement of QoL within 
these areas, providing high quality measurement of the issues that most affect patients.  
The availability of a large number of needs-based QoL measures also offers further 
opportunity to co-calibrate across several diseases areas as described in Chapter 7. This 
approach could help to replace the use of older generic outcome measures that are used 
for this purpose. It could also be applied in comparative effectiveness studies where the 
relative effectiveness of different therapeutic interventions need to be compared. Research 
is required to assess whether the process will have value for this purpose. 
Developing a clearer understanding of the underlying mechanisms that drive our constructs 
is also necessary. This will lead to better construct definition and more accurate, purposeful 
measurement. Future research will attempt to identify the underlying measurement 
mechanism of the needs-based QoL construct.   
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Appendix 2: Sample of the PRIMUS questionnaire 
 
 
 
 
 
 
 
 
 
 
 
 
Please read this carefully 
 
 
This booklet asks about your experience  
of having MS.  
 
Please follow carefully the instructions for each section  
and choose the response that best applies to you. 
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Symptoms 
Please read each question carefully and decide whether it has applied to you during 
the last week. Put a tick in the box  next to ‘Yes’ if you feel it applied to you and 
a tick in the box  next to ‘No’ if it did not. 
  
 
  
 
  
 
1.   Has your skin been very sensitive?  
Yes 
No 
 
 
2.   Have you experienced weakness in your arms or legs? 
Yes 
No 
 
 
3.   Has your eyesight been blurred? 
Yes 
No 
 
 
 
  
 
  
 
  
4.   Have you had dizzy spells? 
Yes 
No 
 
 
5.   Have you had any muscle spasms? 
Yes 
No 
 
 
6.   Have you had any loss of vision? 
Yes 
No 
 
 
7.   Have you been forgetting things? 
Yes 
No 
 
 
  
 
  
 
  
 
8.   Have you had any numbness? 
Yes 
No 
 
 
9.   Have you had urinary incontinence? 
Yes 
No 
 
 
10.   Have you had bowel incontinence? 
Yes 
No 
 
 
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Appendix 3: Sample of the U-FIS questionnaire 
Fatigue Impact Scale (U-FIS) 
 
Below is a list of items that describe the impact of fatigue on people’s lives. Please circle 
the response that best applies to you for each item.  
 
Due to your fatigue, over the last week how much of the time have you…? 
 
 
 Never 
A little 
of the 
time 
About 
half the 
time 
A lot of 
the time 
All the 
time 
1 Run out of energy quickly 0 1 2 3 4 
2 Lacked motivation to engage in social 
activities 0 1 2 3 4 
3 Had difficulty dealing with anything new 0 1 2 3 4 
4 Found it difficult to organise your thoughts 
while doing things at home or at work  0 1 2 3 4 
5 Found normal day-to-day events stressful 0 1 2 3 4 
6 Had to keep stopping and resting 0 1 2 3 4 
7 Had difficulty finishing tasks that require thinking 0 1 2 3 4 
 
 
 Never A little of the time 
About 
half the 
time 
A lot of 
the time 
All the 
time 
8 Felt you had no energy left for enjoyment/fun 0 1 2 3 4 
9 Not felt alert 0 1 2 3 4 
10 Had to force yourself to do things 0 1 2 3 4 
11 Found it difficult to make decisions 0 1 2 3 4 
12 Found that minor difficulties seem like major difficulties 0 1 2 3 4 
13 Had difficulty paying attention for a long period of time 0 1 2 3 4 
14 Felt unable to meet the demands that people place on you 0 1 2 3 4 
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Appendix 4: Sample of the LCOPD questionnaire 
 
 
 
 
 
 
 
 
 
 
 
Please read this carefully 
 
 
On the following pages you will find some statements that  
have been made by people who have  
Chronic Obstructive Pulmonary Disease (COPD)/breathing problems. 
 
 
Thinking about your COPD/breathing problems, please read each statement carefully and 
tick ‘True’ if the statement applies to you and tick ‘Not True’ if it does not. 
 
Please choose the response that best applies to you  
at the moment. 
 
 
 
© Galen Research Ltd, 2007
LCOPD 
Quality of life questionnaire 
 112 
 
Remember to tick  the box next to the response that best applies to you at the 
moment 
  
 
1.  My illness limits the places I can go 
True 
Not True 
r  
r  
  
 
2.  I get frustrated easily 
True 
Not True 
r  
r  
  
 
3.  I can’t do things on the spur of the moment 
True 
Not True 
r  
r  
  
 
  
 
4.  I feel like a prisoner in my own home 
True 
Not True 
r  
r  
  
 
5.  I worry that I stop people doing what they want to do 
True 
Not True 
r  
r  
  
 
6.  My illness controls me 
True 
Not True 
r  
r  
  
 
  
 
7.  I have to plan even the most simple tasks carefully 
True 
Not True 
r  
r  
  
 
8.  My breathing makes me self conscious 
True 
Not True 
r  
r  
  
 
9.  I have to pace myself 
True 
Not True 
r  
r  
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Appendix 5: Sample of the ALIS questionnaire 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Please read this carefully 
 
 
On the following pages you will find some statements that have been made by 
people who have asthma. 
 
 
Thinking about your asthma, please read each statement carefully  
and tick ‘True’ if the statement applies to you and tick ‘Not True’ if it does not. 
 
Please choose the response that best applies to you  
at the moment. 
 
 
© Galen Research Ltd, 2007 
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Remember to tick  the box next to the response that best applies to you at the moment 
1.  Asthma stops me being adventurous 
True 
Not True 
r  
r  
   
2.  I feel dependent on my treatment 
True 
Not True 
r  
r  
   
3.  I’m unable to join in activities with my friends and family True 
Not True 
r  
r  
 
  
 
  
4.  I feel older than my years 
True 
Not True 
r  
r  
   
5.  I have to pace myself 
True 
Not True 
r  
r  
   
6.  My self-confidence is affected 
True 
Not True 
r  
r  
   
   
7.  I constantly have to think about my medication 
True 
Not True 
r  
r  
   
8.  I have to limit what I do each day 
True 
Not True 
r  
r  
 
9.  I feel like I let other people down 
True 
Not True 
r  
r  
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Appendix 6: Sample of the CAMPHOR questionnaire 
 
 
 
 
 
 
 
 
 
Please read this carefully 
 
 
On the following pages you will find some statements that  
have been made by people who have Pulmonary Arterial Hypertension. 
 
Please read each statement carefully.   
We would like you to put a tick in the box  next to ‘Yes’  
if you feel it applies to you and a tick in the  
box  next to ‘No’ if it does not 
 
Please choose the response that applies best to you 
at the moment 
 
 
© Galen Research & Papworth Hospital, 2004 
 
 
CAMPHOR 
Cambridge Pulmonary Hypertension 
Outcome Review 
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Symptoms 
 
 Please read each statement carefully and decide whether it applies to you  at the 
moment  
  
 
1.   My stamina levels are low  
Yes  
No  
 
 
 
2.   I have to rest during the day  
Yes  
No  
 
 
 
3.   I feel worn out 
Yes  
No  
 
 
 
 
 
 
 
 
 
4.   I get tired very quickly 
Yes  
No  
 
 
 
5.   I’m tired all the time 
Yes  
No  
 
 
 
6.   I feel very weak 
Yes  
No  
 
 
 
 
 
 
 
 
 
7.   I feel completely exhausted   Yes  
No  
 
 
 
8.   I want to sit down all the time Yes  
No  
 
 
 
9.   I soon run out of energy Yes  
No  
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Appendix 7: Sample of the PSORIQoL questionnaire 
 
 
 
 
 
 
 
 
 
PSORIQoL 
 
 
 
 
 
 
PLEASE READ THIS CAREFULLY 
 
 
On the following pages you will find some statements 
that have been made by people with psoriasis. 
 
We would like you to tick ‘True’ if the statement applies to you 
and tick ‘Not True’ if it does not. 
 
Please choose the response that applies best to you 
 
AT THE MOMENT 
 
 
 
© Novartis Pharma AG & Galen Research, 2001 
 
 
 
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Please read each statement carefully and decide whether it applies 
to you  at the moment  
 
  
 
  
 
  
 
  
 
 True r  
1.   I worry about what other people think of me     
 Not True r  
   
   
   
 True r  
2.   I never feel clean    
 Not True r  
   
   
   
 True r  
3.   I hate people seeing my skin    
 Not True r  
   
   
   
   
   
   
 True r  
4.   I have no self-confidence    
 Not True r  
   
   
   
 True r  
5.   I can’t enjoy myself when I go out    
 
Not True r  
   
   
   
 True r  
6.   Psoriasis rules my life    
 Not True r  
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Appendix 8: Sample of the QoLIAD questionnaire 
 
 
 
 
 
 
 
 
QoLIAD 
 
 
 
 
 
 
PLEASE READ THIS CAREFULLY 
 
 
On the following pages you will find some statements 
that have been made by people with eczema. 
 
We would like you to tick ‘True’ if the statement applies to you 
and tick ‘Not True’ if it does not. 
 
Please choose the response that applies best to you 
 
AT THE MOMENT 
 
 
 
© Novartis Pharma AG & Galen Research, 2000 
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Please read each statement carefully and decide whether it applies 
to you  at the moment  
  
  
  
  
  True r  
 1.    I worry about my appearance  
  Not True r  
  
  
  
  True r  
 2.    I have no self-confidence  
  Not True r  
  
  
  
  True r  
 3.    I avoid physical contact  
  Not True r  
  
  
  
  
  
  
  
  True r  
 4.    I get embarrassed when I am with people I don’t know very well  
  Not True r  
  
  
  
  True r  
 5.    My life revolves around my condition  
  Not True r  
  
  
  
  True r  
 6.    I feel tense all the time  
  Not True r  
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Glossary 
ANOVA Analysis of variance 
Classical Test Theory (CTT) An approach to the design, analysis and scoring of 
tests. It is based on true score theory. The approach 
uses predominantly correlational based methods and 
produces measures at the ordinal level of 
measurement. 
Co-calibration A method of placing two different PROs onto the same 
measurement scale using Item Response Theory.  
Conceptual framework This explains the structure of a PRO and shows the 
relation between items, domains and the overall 
construct measured. It is usually organised in the form 
of a figure. 
Construct An idea or concept used to explain something. PROs 
aim to measure different kinds of constructs. 
Construct validity A PRO is considered to have construct validity if it 
measures what it intends to measure. It is assessed 
using different approaches such as known group 
validity.  
Convergent validity This assesses the validity of a PRO by relating it other 
available outcome measures that assess similar 
constructs. Higher correlations should be observed 
between constructs that are more similar.  
Content analysis This involves conducting thematic analysis on 
interview data. The topic of interest is coded into 
themes of related issues. Themes are then harmonized 
until an understanding of the area is developed.  
Common person design A method of co-calibrating scales that requires 
patients to have completed both of the scales that are 
to be combined.   
Common item design A method of co-calibrating scales that requires overlap 
in item content.  
Cronbach’s alpha coefficient The Cronbach’s alpha coefficient is used to assess the 
extent to which the items in a scale are inter-related. It 
is the primary method of assessing internal reliability 
under Classical Test Theory.  
Differential item functioning This is a statistical method applied in Item Response 
Theory. It is used to assess whether answers to items 
are biased by different subgroups (such as those 
defined by age or gender). This kind of bias causes 
instability in the severity ordering of the items.    
Dual panel translation A method of translating a questionnaire that uses two 
translation panels. The first panel consists of group of 
bilingual speakers that work together to translate the 
questionnaire. The second panel consists of 
monolingual speakers of the local language. The role 
of the second group is to make sure the language 
selected is easily understood by the target population.   
Effect size This is used to quantify the strength of an observation. 
It is calculated by dividing the difference between two 
mean scores by the standard deviation at baseline. 
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Factor analysis This includes a group of statistical methods that are 
used to identify the relations between a set of 
variables or questionnaire items in order to group 
them into a smaller number of explanatory domains. 
The methods are based on correlational techniques.  
Forward-backward translation A method of PRO translation conducted by a linguistic 
expert. After translation the content of the PRO is 
translated back into the original source language by a 
second person. The original and back translated 
questionnaires are then compared and any 
discrepancies resolved.   
Guttman scale A Guttman scale is a measure in which the items are 
ranked in order of difficulty from least extreme to 
most extreme. Correct answers to the Guttman scale 
would follow the ordering of the items precisely. A 
person that answers question 8 correctly would also 
answer questions 1-7 correctly. 
Health related quality of life 
(HRQL) 
An approach to PRO measurement based on assessing 
different sub-domains relating to a person’s health. 
Such approaches predominantly measure symptoms 
and functional limitations.  
Interval level measurement Numerical scales where the distances between each 
part of the scale are the same throughout.  
Intra-class correlation A correlation statistic that accounts for both within-
subject change and systematic change in the mean.  
Item and person interaction 
statistics 
Used to assess fit to the Rasch model. These 
assessments measure the extent to which observed 
item and person estimates deviate from the expected.   
Item response theory Includes a group of models that are concerned with 
the design, analysis and scoring of tests. Each item is 
assumed to represents a different level of difficulty. 
IRT models the response of patients of a given ability 
to an item of a given difficulty. 
Known group validity This assesses the validity of a PRO by relating it to 
groups of known importance. For example, scores on 
the PRO can be related to groups representing 
different levels of disease severity.   
Latent variable A variable that is not directly observable but is 
inferred. 
Local dependency A requirement of the Rasch model is the local 
independence of items. Local dependency occurs 
when items are too closely related such that the 
response to one item has too strong an influence over 
answers to another item. 
Measurement mechanism This is an approach to construct definition whereby 
the underlying mechanism of the measure is 
understood so that items can be manipulated to 
represent varying levels of the construct of interest.   
Minimal important difference 
(MID) 
A change score on a measure that represents a 
minimal level of meaningfulness to the patient.  
Needs-based QoL A definition of quality of life based on the satisfaction 
of human needs. Quality of life is high when more 
needs are met.  
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Ordinal level measurement A type of measurement where individuals can be 
ranked but the distances between levels on the scale 
are unequal. 
Overall item-trait interaction Chi
2
 
fit value 
Used to assess overall fit to the Rasch model 
expectations. A significant Ch
2 
value indicates misfit to 
model expectations. 
Patient reported outcome (PRO) A measure in the form of a questionnaire used to 
capture information relating to a person’s health. 
Pearson correlation A parametric correlation statistic.  
Person separation index (PSI) This is a form of reliability statistic that can be 
calculated within the Rasch framework and is 
indicative of the power of the items to distinguish 
between respondents. 
Qualitative interviews These are open ended interviews in which patients 
experience with a given topic is explored. The 
interviews are usually transcribed and then analysed 
thematically.  
Rasch analysis The Rasch model is a simple logistic one parameter 
item response theory model with strong mathematical 
properties. Measures that fit the model provide 
interval level measurement.  
Responder definition A change score on a measure that represents a 
minimal level of meaningfulness to the patient. It is 
also referred to as minimal important difference 
(MID).  
Response threshold A response threshold is the point between two 
adjacent response categories where the probability of 
endorsing either category reaches 0.5. Response 
thresholds are used within a Rasch framework to 
assess whether the response options function logically.  
Receiving operating characteristic 
(ROC) curve analysis 
A ROC curve analysis is a graphic plot used to assess 
how well a screening tool classifies individuals at 
different cut-off levels.    
RUMM program A statistical package used to assess fit to the Rasch 
model.  
Sensitivity analysis This is used to assess the functioning of a screening 
tool. It measures the proportion of positives that are 
correctly identified as such for a given score on a 
measure.  
Specificity analysis This is used to assess the functioning of a screening 
tool. It measures the proportion of negatives correctly 
measured as such for a given score on a measure. 
Specification equation An explanation of the underlying mechanisms that 
make items represent different levels of the construct 
of interest. 
Spearman Rank correlation A non-parametric correlation statistic. 
Standard error of measurement This is considered to be an assessment of how much 
the persons observed score is affected by the error 
inherent in the test. It is calculated using the standard 
deviation at baseline and the internal consistency of 
the measure.  
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Test-retest reliability This is a measure of the reproducibility of a 
questionnaire. A high correlation should be observed 
between scores on a test when no change in condition 
has taken place.   
True score theory This is the underlying paradigm of Classical Test 
Theory. It is based on the assumption that scores on a 
test are obscured by the error that is inherent in the 
test. Scores are comprised of ‘true score + error’.  
Unidimensionality The property of measuring a single underlying 
dimension. Measures that fit the Rasch model hold 
this property.  
WHO functional class A classification of disease severity for pulmonary 
hypertension. It is clinician completed and comprises 
four different severity groups. 
 
